var title_f0_22_352="Blurred spine in osteomalacia";
var content_f0_22_352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypophosphatemic osteomalacia: Radiographic findings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spine films in a 37-year-old man with osteomalacia. The main findings are decreased bone density, with blurring and deformity of the spine. The blurring makes the films appear of low quality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of CJ Menkes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_352=[""].join("\n");
var outline_f0_22_352=null;
var title_f0_22_353="Corn - fifth toe";
var content_f0_22_353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperkeratotic papule with a central \"core\" is present on the lateral fifth toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_353=[""].join("\n");
var outline_f0_22_353=null;
var title_f0_22_354="Peutz Jeghers colonic polyp";
var content_f0_22_354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peutz-Jeghers polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross picture of an intestinal polyp (arrow) removed from a patient with the Peutz-Jeghers syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_354=[""].join("\n");
var outline_f0_22_354=null;
var title_f0_22_355="Patient information: Toe fracture (The Basics)";
var content_f0_22_355=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83613\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/61/27600\">",
"         Foot and toe bones",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/51/42813\">",
"          Buddy taping of the toes",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"           Foods and drinks with calcium and vitamin D",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/51/11058\">",
"         Patient information: Cast and splint care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Toe fracture (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/toe-fracture-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H869505940\">",
"      <span class=\"h1\">",
"       What is a toe fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A &ldquo;fracture&rdquo; is another word for a broken bone. A toe fracture is when a person breaks a bone in the toe (",
"      <a class=\"graphic graphic_figure graphicRef83480 \" href=\"UTD.htm?26/61/27600\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      There are different types of toe fractures. The type of toe fracture depends on which toe bone breaks and how it breaks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H869505972\">",
"      <span class=\"h1\">",
"       What are the symptoms of a toe fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of a toe fracture can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Bruising",
"       </li>",
"       <li>",
"        Trouble walking",
"       </li>",
"       <li>",
"        A crooked-looking toe",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H869505987\">",
"      <span class=\"h1\">",
"       Is there a test for a toe fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms, do an exam, and order an X-ray of your toe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H869506002\">",
"      <span class=\"h1\">",
"       How is a toe fracture treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of toe fracture you have and how severe it is.",
"     </p>",
"     <p>",
"      Treatment for a toe fracture usually involves:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Resting your foot",
"       </li>",
"       <li>",
"        Raising your foot above the level of your heart, for example, by propping it up on pillows &ndash; This is helpful only for the first few days after an injury.",
"       </li>",
"       <li>",
"        Putting ice on your toe &ndash; Put a cold gel pack, bag of ice, or bag of frozen vegetables on the toe every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and the skin. Use the ice (or other cold object) for at least 6 hours after the injury. Some people find it helpful to ice up to 2 days after the injury.",
"       </li>",
"       <li>",
"        Buddy taping (",
"        <a class=\"graphic graphic_figure graphicRef83507 \" href=\"UTD.htm?41/51/42813\">",
"         figure 2",
"        </a>",
"        ) &ndash; This involves taping the injured toe to the toe next to it. The doctor or nurse will put some cotton or other soft material between your toes so they don&rsquo;t rub together.",
"       </li>",
"       <li>",
"        Wearing a cast or special hard-soled shoe &ndash; Most people can put weight on their foot and walk around while wearing a cast. Before your doctor puts a cast on your foot, he or she will make sure your toe bones are in the correct position. If your bones are not in the correct position, he or she might need to do a procedure to put your bones back in the correct position.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will also treat your pain. If you have a lot of pain or a severe fracture, your doctor will prescribe a strong pain medicine. If your fracture is mild, your doctor might recommend that you take an over-the-counter pain medicine. Over-the-counter pain medicines include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H869506040\">",
"      <span class=\"h1\">",
"       How long does a toe fracture take to heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A toe fracture usually takes weeks to heal, depending on the type of fracture.",
"     </p>",
"     <p>",
"      Healing time also depends on the person. Healthy children usually heal much more quickly than older adults or adults with other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H869506055\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to follow all of your doctor&rsquo;s instructions while your fracture is healing. This includes instructions about when you can put weight on your foot.",
"     </p>",
"     <p>",
"      Doctors also usually recommend that people with a fracture:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eat a healthy diet that includes getting enough calcium, vitamin D, and protein (",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"UTD.htm?18/13/18647\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Avoid getting the cast wet, if it&rsquo;s a cast that shouldn&rsquo;t get wet.",
"       </li>",
"       <li>",
"        Stop smoking. Fractures can take longer to heal if people smoke.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H869506093\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor or nurse will tell you when to call him or her. In general, you should call him or her if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have severe pain.",
"       </li>",
"       <li>",
"        Your pain, swelling, or bruising gets worse.",
"       </li>",
"       <li>",
"        You have numbness or tingling in your toes.",
"       </li>",
"       <li>",
"        You damage your cast or get it wet, and it&rsquo;s not supposed to get wet.",
"       </li>",
"       <li>",
"        Your cast is too tight or too loose.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H869506108\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       Patient information: Cast and splint care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/22/355?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83613 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-49B032D4AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_355=[""].join("\n");
var outline_f0_22_355=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H869505940\">",
"      What is a toe fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H869505972\">",
"      What are the symptoms of a toe fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H869505987\">",
"      Is there a test for a toe fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H869506002\">",
"      How is a toe fracture treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H869506040\">",
"      How long does a toe fracture take to heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H869506055\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H869506093\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H869506108\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83613\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/61/27600\">",
"      Foot and toe bones",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/51/42813\">",
"       Buddy taping of the toes",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"        Foods and drinks with calcium and vitamin D",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_22_356="B-Lynch suture";
var content_f0_22_356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Anterior uterine wall with B-Lynch suture in place and an enlarged drawing (box) of lower uterine segment with B-Lynch suture in place",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 517px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large Mayo needle with #2 chromic catgut is used to enter and exit the uterine cavity at A and B. The suture is looped over the fundus and then reenters the uterine cavity posteriorly at C, which is directly below B. The suture should be pulled very tight at this point. It then enters the posterior wall of the uterine cavity at D, is looped back over the fundus, and anchored by entering the anterior lateral lower uterine segment at E and crossing through the uterine cavity to exit at F. The free ends at A and F are tied down securely to compress the uterus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Obstetrics &amp; Gynecology Case Reports &amp; Reviews, Vol. 95, Num 6, June 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_356=[""].join("\n");
var outline_f0_22_356=null;
var title_f0_22_357="Methyclothiazide: Patient drug information";
var content_f0_22_357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methyclothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/36/16965?source=see_link\">",
"     see \"Methyclothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methyclothiazide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10859 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-2F27AEB7FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_357=[""].join("\n");
var outline_f0_22_357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019973\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019975\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019974\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019979\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019980\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019982\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019977\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019978\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019983\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019984\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/36/16965?source=related_link\">",
"      Methyclothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_22_358="Metformin: Patient drug information";
var content_f0_22_358=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Metformin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     see \"Metformin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/59/13238?source=see_link\">",
"     see \"Metformin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fortamet&reg;;",
"     </li>",
"     <li>",
"      Glucophage&reg;;",
"     </li>",
"     <li>",
"      Glucophage&reg; XR;",
"     </li>",
"     <li>",
"      Glumetza&reg;;",
"     </li>",
"     <li>",
"      Riomet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metformin&reg;;",
"     </li>",
"     <li>",
"      Ava-Metformin;",
"     </li>",
"     <li>",
"      CO Metformin;",
"     </li>",
"     <li>",
"      Dom-Metformin;",
"     </li>",
"     <li>",
"      Glucophage&reg;;",
"     </li>",
"     <li>",
"      Glumetza&reg;;",
"     </li>",
"     <li>",
"      Glycon;",
"     </li>",
"     <li>",
"      JAMP-Metformin;",
"     </li>",
"     <li>",
"      JAMP-Metformin Blackberry;",
"     </li>",
"     <li>",
"      Med-Metformin;",
"     </li>",
"     <li>",
"      Mylan-Metformin;",
"     </li>",
"     <li>",
"      Novo-Metformin;",
"     </li>",
"     <li>",
"      Nu-Metformin;",
"     </li>",
"     <li>",
"      PHL-Metformin;",
"     </li>",
"     <li>",
"      PMS-Metformin;",
"     </li>",
"     <li>",
"      PRO-Metformin;",
"     </li>",
"     <li>",
"      Q-Metformin;",
"     </li>",
"     <li>",
"      RAN&trade;-Metformin;",
"     </li>",
"     <li>",
"      ratio-Metformin;",
"     </li>",
"     <li>",
"      Riva-Metformin;",
"     </li>",
"     <li>",
"      Sandoz-Metformin FC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A small number of people may have more acid in their blood. Metformin may cause this. It may happen in people whose liver or kidneys do not work the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes). It may take 1 month to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3072780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop high blood sugar (diabetes).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be used to help hormone balance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give the extended release product to a child younger than 17 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metformin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, drink too much alcohol, fluid loss, kidney disease, or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having an x-ray with dye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug for 2 days after you have an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you are having surgery, if you have had a heart attack, bad infection, or stroke, or if you are 80 years of age or older and have not had your kidney function tested.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much acid in the blood (lactic acidosis) may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take long-acting products at dinner.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694919",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fortamet&reg;: Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11790 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_358=[""].join("\n");
var outline_f0_22_358=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193858\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193859\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018781\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018783\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018782\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018787\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018788\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018790\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018785\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018786\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018791\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018792\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=related_link\">",
"      Metformin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/59/13238?source=related_link\">",
"      Metformin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_22_359="Epoprostenol: Drug information";
var content_f0_22_359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epoprostenol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/61/20436?source=see_link\">",
"    see \"Epoprostenol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/63/22519?source=see_link\">",
"    see \"Epoprostenol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flolan&reg;;",
"     </li>",
"     <li>",
"      Veletri&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flolan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Prostacyclin;",
"     </li>",
"     <li>",
"      Prostaglandin;",
"     </li>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pulmonary arterial hypertension (PAH):",
"     </b>",
"     I.V.: Initial: 2 ng/kg/minute; a lower initial dose may be used if patient is intolerant of starting dose.  Increase dose in increments of 2 ng/kg/minute at intervals of &ge;15 minutes until dose-limiting side effects (eg, flushing, jaw pain, headache, hypotension, nausea) are noted or response to epoprostenol plateaus. Usual optimal dose (monotherapy): 25-40 ng/kg/minute (McLaughlin, 2009); significant patient variability in optimal dose exists. Maximum dose with chronic therapy has not been defined; however, doses as high as 195 ng/kg/minute have been described in children (Rosenzweig, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Dose adjustment during chronic phase of treatment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If PAH symptoms persist or recur following improvement, increase dose in 1-2 ng/kg/minute increments at intervals of &ge;15 minutes. May also increase dose at intervals of 24-48 hours or longer (eg, every 1-2 weeks).",
"     <b>",
"      Note:",
"     </b>",
"     The need for increased doses should be expected with chronic use; incremental increases occur more frequently during the first few months after the drug is initiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     In case of dose-limiting pharmacologic events (eg, hypotension, severe nausea, vomiting), decrease dose in 2 ng/kg/minute decrements at intervals of &ge;15 minutes. Avoid abrupt withdrawal or sudden large dose reductions.",
"     <b>",
"      Note:",
"     </b>",
"     Adverse event may resolve without dosage adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lung transplant: In patients receiving lung transplants, epoprostenol may be tapered after sequential lung transplantation once the allografts have been reperfused. If cardiopulmonary bypass utilized, epoprostenol may be tapered after pump perfusion has been initiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute vasodilator testing in patients with PAH (unlabeled use; McLaughlin, 2009):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Acute vasodilator testing should only be done in patients who might be considered candidates for calcium channel blocker therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Initial: 2 ng/kg/minute; increase dose in increments of 2 ng/kg/minute every 10-15 minutes; dosing range during testing: 2-10 ng/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Intraoperative pulmonary hypertension during cardiac surgery with cardiopulmonary bypass (CPB) (unlabeled use):",
"     </b>",
"     Inhalation (unlabeled route):",
"     <b>",
"      Note:",
"     </b>",
"     Institution-specific protocols vary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Administration after induction of anesthesia before incision: 60 mcg (4 mL of 15,000 ng/mL concentration) via jet nebulizer; effect persists for ~25 minutes (Hache, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Intraoperative administration:",
"     <i>",
"      Nebulization via ventilator circuit:",
"     </i>",
"     Using a 15,000 ng/mL concentration and an oxygen flow of 8 L/minute, begin administration via jet nebulizer 5 minutes prior to weaning from CPB; discontinue at least 60 minutes after CPB weaned (Fattouch, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Post-cardiothoracic surgery pulmonary hypertension, right ventricular dysfunction, or refractory hypoxemia (unlabeled use) (DeWet, 2004):",
"     </b>",
"     Inhalation (unlabeled route):",
"     <b>",
"      Note:",
"     </b>",
"     May need to change ventilator filter every 2 hours due to glycine buffer diluent; may cause ventilator valve malfunction. Tidal volume delivered by ventilator may require adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Nebulization via ventilator circuit:",
"     </i>",
"     Using a 20,000 ng/mL concentration, prime nebulizer chamber with 15 mL; administer remainder at a constant rate of 8 mL/hour; delivers ~38 ng/kg/minute (based on a 70 kg patient); set oxygen flow at 2-3 L/minute; wean as tolerated.",
"     <b>",
"      Note:",
"     </b>",
"     Although not achieved with this regimen, in general, doses &gt;50 ng/kg/minute do not provide additional benefit and may increase the risk of hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Nebulization via facemask with Venturi attachment:",
"     </i>",
"     Using a 20,000 ng/mL concentration, prime nebulizer chamber with 15 mL; set oxygen flow at 2-3 L/minute; 8 mL/hour will be nebulized; wean as tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Weaning procedure: Reduce dose by 50% every 2-4 hours (ie, 20,000 ng/mL to 10,000 ng/mL to 5000 ng/mL) until a concentration of 2500 ng/mL is reached; carefully discontinue once patient remains stable on this concentration for at least 4 hours.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2521393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/63/22519?source=see_link\">",
"      see \"Epoprostenol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pulmonary arterial hypertension (PAH):",
"     </b>",
"     Unlabeled use; refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15822433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 0.5 mg, 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flolan&reg;: 0.5 mg, 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Veletri&reg;: 1.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Orders for epoprostenol are distributed by two sources in the United States. Information on orders or reimbursement assistance may be obtained from either Accredo Health, Inc (1-800-935-6526) or TheraCom, Inc (1-877-356-5264).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F165841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: The ambulatory infusion pump should be small and lightweight, be able to adjust infusion rates in 2 ng/kg/minute increments, have occlusion, end of infusion, and low battery alarms, have &plusmn; 6% accuracy of the programmed rate, and have positive continuous or pulsatile pressure with intervals &le;3 minutes between pulses. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Immediate access to back up pump, infusion sets and medication is essential to prevent treatment interruptions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Inhalation (unlabeled route):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Intraoperative administration: Administer via jet nebulizer connected to the inspiratory limb of the ventilator near the endotracheal tube with a bypass oxygen flow of 8 L/minute to achieve administration of a high proportion of small particles (Fattouch, 2006; Hache, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Post-cardiothoracic surgery: May also be administered via jet nebulizer connected to the inspiratory limb of the ventilator near the endotracheal tube or via face mask with a Venturi attachment for aerosolization with a bypass oxygen flow of 2-3 L/minute (De Wet, 2004).",
"     <b>",
"      Note:",
"     </b>",
"     Glycine buffer diluent may cause ventilator valve malfunction; it has been recommended that filters be changed on the ventilator every 2 hours; may also use a ventilator heating coil (De Wet, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F165885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Flolan&reg;: Only prepare with sterile diluent provided. Veletri&reg;: Only prepare with SWFI or NS. Per manufacturer, do not mix or administer with any other drugs or solutions prior to or during administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in Y-site administration: Compatible:",
"     </b>",
"     Bivalirudin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA Class III or IV symptoms to improve exercise capacity",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7730063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute vasodilator testing in pulmonary arterial hypertension (PAH)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Inhalation: Intraoperative treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass; post-cardiothoracic surgery pulmonary hypertension, right ventricular dysfunction, or refractory hypoxemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse events reported during dose initiation and escalation include flushing (58%), headache (49%), nausea/vomiting (32%), hypotension (16%), anxiety/nervousness/agitation (11%), chest pain (11%); dizziness, abdominal pain, bradycardia, musculoskeletal pain, dyspnea, back pain, diaphoresis, dyspepsia, hypoesthesia/paresthesia, and tachycardia are also reported. Although some adverse reactions may be related to the underlying disease state, abdominal pain, anxiety/nervousness/agitation, arthralgia, bleeding, bradycardia, diarrhea, diaphoresis, flu-like syndrome, flushing, headache, hypotension, jaw pain, nausea, pain, pulmonary edema, rash, tachycardia, thrombocytopenia, and vomiting are clearly contributed to epoprostenol. The following adverse events have been reported during chronic administration for idiopathic or heritable PAH:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (35% to 43%), flushing (23% to 42%), hypotension (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (83%), headache (46% to 83%), chills/fever/sepsis/flu-like syndrome (25%), anxiety/nervousness/tremor (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin ulcer (39%), eczema/rash/urticaria (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (41% to 67%), anorexia (66%), diarrhea (37% to 50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Infection (18%), pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Pain/neck pain/arthralgia (84%), jaw pain (54% to 75%), arthritis (52%), myalgia (44%), musculoskeletal pain (35%), hypoesthesia/hyperesthesia/paresthesia (5% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports: Anemia, fatigue, hepatic failure, hypersplenism, hyperthyroidism, pallor, pancytopenia, pulmonary embolism, splenomegaly, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to epoprostenol or to structurally-related compounds; chronic use in patients with heart failure due to severe left ventricular systolic dysfunction; patients who develop pulmonary edema during dose initiation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary edema: Some patients with PAH have developed pulmonary edema during dosing adjustment and acute vasodilator testing (not an approved use), which may be associated with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rebound pulmonary hypertension: Abrupt interruptions or large sudden reductions in dosage may result in rebound pulmonary hypertension. Avoid abrupt withdrawal. Immediate access to medication or pump and infusion sets is essential to prevent treatment interruptions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions that increase bleeding risk: Epoprostenol is an inhibitor of platelet aggregation. Use with caution in patients with risk factors for bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants: During chronic use, unless contraindicated, anticoagulants should be coadministered to reduce the risk of thromboembolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate Use: Initiation or transition to epoprostenol requires specialized cardiopulmonary monitoring in a critical care setting where clinicians are experienced in advanced management of pulmonary arterial hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Chronic continuous I.V. infusion of epoprostenol via a chronic indwelling central venous catheter (CVC) has been associated with local infections and serious blood stream infections.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F165832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Prostacyclin Analogues may enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Prostacyclin Analogues may enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2521390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not reported in animal studies. There are no adequate and well-controlled studies in pregnant women. Women with IPAH are encouraged to avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Epoprostenol Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (1): $14.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (1): $34.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Flolan Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (1): $22.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (1): $54.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Veletri Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (1): $27.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (1): $45.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F165836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for improvements in pulmonary function, decreased exertional dyspnea, fatigue, syncope and chest pain, pulmonary vascular resistance, pulmonary arterial pressure and quality of life. In addition, the pump device and catheters should be monitored frequently to avoid &ldquo;system&rdquo; related failure. Monitor arterial pressure; assess all vital functions. Hypoxia, flushing, and tachycardia may indicate overdose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Flolan (AT, AU, BE, CH, CZ, DK, EE, ES, FR, GB, GR, IE, IL, IT, NL, NO, PL, SG, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epoprostenol is also known as prostacyclin and PGI",
"     <sub>",
"      2",
"     </sub>",
"     . It is a strong vasodilator of all vascular beds. In addition, it is a potent endogenous inhibitor of platelet aggregation. The reduction in platelet aggregation results from epoprostenol's activation of intracellular adenylate cyclase and the resultant increase in cyclic adenosine monophosphate concentrations within the platelets. Additionally, it is capable of decreasing thrombogenesis and platelet clumping in the lungs by inhibiting platelet aggregation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hydrolyzed; subject to some enzymatic degradation; forms two active metabolites (6-keto-prostaglandin F",
"     <sub>",
"      1",
"     </sub>",
"     &alpha; and 6,15-diketo-13,14-dihydro-prostaglandin F",
"     <sub>",
"      1",
"     </sub>",
"     &alpha;) with minimal activity and 14 inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~6 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (84%); feces (4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Badesch DB, Abman SH, Simonneau G, et al, &ldquo;Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 131(6):1917-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/17565025/pubmed\" id=\"17565025\" target=\"_blank\">",
"        17565025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Badesch DB, Tapson VF, McGoon MD, et al,&ldquo;Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2000, 21;132(6):425-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/10733441/pubmed\" id=\"10733441\" target=\"_blank\">",
"        10733441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barst RJ, Maislin G, and Fishman AP, &ldquo;Vasodilator Therapy for Primary Pulmonary Hypertension in Children,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(9):1197-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/10069788/pubmed\" id=\"10069788\" target=\"_blank\">",
"        10069788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barst RJ, Rubin LJ, Long WA, et al, &ldquo;A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) With Conventional Therapy for Primary Pulmonary Hypertension. The Primary Pulmonary Hypertension Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(5):296-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/8532025/pubmed\" id=\"8532025\" target=\"_blank\">",
"        8532025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cremona G and Higenbottam T, &ldquo;Role of Prostacyclin in the Treatment of Primary Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1995, 75(3):67A-71A.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/7840058/pubmed\" id=\"7840058\" target=\"_blank\">",
"        7840058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Wet CJ, Affleck DG, Jacobsohn E, et al, &ldquo;Inhaled Prostacyclin is Safe, Effective, and Affordable in Patients with Pulmonary Hypertension, Right Heart Dysfunction, and Refractory Hypoxemia After Cardiothoracic Surgery,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 2004, 127(4):1058-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/15052203/pubmed\" id=\"15052203\" target=\"_blank\">",
"        15052203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fattouch K, Sbraga F, Sampognaro R, et al, &ldquo;Treatment of Pulmonary Hypertension in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Randomized, Prospective, Double-Blind Study,&rdquo;",
"      <i>",
"       J Cardiovasc Med (Hagerstown)",
"      </i>",
"      , 2006, 7(2):119-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/16645371/pubmed\" id=\"16645371\" target=\"_blank\">",
"        16645371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hach&eacute;, M, Denault A, B&eacute;lisle S, et al, &ldquo;Inhaled Epoprostenol (Prostacyclin) and Pulmonary Hypertension Before Cardiac Surgery,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 2003, 125(3):642-9",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/12658208/pubmed\" id=\"12658208\" target=\"_blank\">",
"        12658208",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Higenbottam TW, Spiegelhalter D, Scott JP, et al, &ldquo;Prostacyclin (Epoprostenol) and Heart-Lung Transplantation as Treatments for Severe Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Br Heart J",
"      </i>",
"      , 1994, 70:366-70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones DK, Higenbottam TW, and Wallwork J, &ldquo;Treatment of Primary Pulmonary Hypertension Intravenous Epoprostenol (Prostacyclin),&rdquo;",
"      <i>",
"       Br Heart J",
"      </i>",
"      1987, 57(3):270-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(16):2250-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/19332472/pubmed\" id=\"19332472\" target=\"_blank\">",
"        19332472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Genthner DE, Panella MM, et al, &ldquo;Reduction in Pulmonary Vascular Resistance With Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(5):273-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/9445406/pubmed\" id=\"9445406\" target=\"_blank\">",
"        9445406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Shillington A, and Rich S, &ldquo;Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 106(12):1477-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/12234951/pubmed\" id=\"12234951\" target=\"_blank\">",
"        12234951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakayama T, Shimada H, Takatsuki S, et al, &ldquo;Efficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children,&rdquo;",
"      <i>",
"       Circ J",
"      </i>",
"      , 2007, 71(11):1785-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/17965503/pubmed\" id=\"17965503\" target=\"_blank\">",
"        17965503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rich S, Kaufmann E, and Levy PS, &ldquo;The Effect of High Doses of Calcium-channel Blockers on Survival in Primary Pulmonary Hypertension,&rdquo;",
"      <i>",
"       N Engl J Med,",
"      </i>",
"      1992, 327(2):76-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/1603139/pubmed\" id=\"1603139\" target=\"_blank\">",
"        1603139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenzweig EB and Barst RJ, &ldquo;Idiopathic Pulmonary Arterial Hypertension in Children,&rdquo;",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 2005, 17(3):372-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/15891429/pubmed\" id=\"15891429\" target=\"_blank\">",
"        15891429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenzweig EB, Kerstein D, and Barst RJ, \"Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(14):1858-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/10199883/pubmed\" id=\"10199883\" target=\"_blank\">",
"        10199883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenzweig EB, Widlitz AC, and Barst RJ, &ldquo;Pulmonary Arterial Hypertension in Children,&rdquo;",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2004, 38(1):2-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/15170869/pubmed\" id=\"15170869\" target=\"_blank\">",
"        15170869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin LJ, Groves BM, Reeves JT, et al, &ldquo;Prostacyclin-Induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1982, 66(2):334-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/7046988/pubmed\" id=\"7046988\" target=\"_blank\">",
"        7046988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitbon O, Humbert M, Nunes H, et al, &ldquo;Long-Term Intravenous Epoprostenol Infusion in Primary Pulmonary Hypertension - Prognostic Factors and Survival,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 40(40):780-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/12204511/pubmed\" id=\"12204511\" target=\"_blank\">",
"        12204511",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sueta CA, Gheorghiade M, Adams KF, et al, &ldquo;Safety and Efficacy of Epoprostenol in Patients With Severe Congestive Heart Failure. Epoprostenol Multicenter Research Group,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1995, 75(3):34A-43A.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/7840053/pubmed\" id=\"7840053\" target=\"_blank\">",
"        7840053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Heerden PV, Barden A, Michalopaoulos N, et al, &ldquo;Dose-Response to Inhaled Aerosolized Prostacyclin for Hypoxemia Due to ARDS,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2000, 117(3):819-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/10713012/pubmed\" id=\"10713012\" target=\"_blank\">",
"        10713012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walmrath D, Schneider T, Pilch J, et al, &ldquo;Aerosolised Prostacyclin in Adult Respiratory Distress Syndrome,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1993, 342(8877):961-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/8105216/pubmed\" id=\"8105216\" target=\"_blank\">",
"        8105216",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widlitz A and Barst RJ, &ldquo;Pulmonary Arterial Hypertension in Childrenl,&rdquo;",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2003, 21(1):155-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/12570125/pubmed\" id=\"12570125\" target=\"_blank\">",
"        12570125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zwissler, B, Kemming G, Habler O, et al, &ldquo;Inhaled Prostacyclin (PGI2) Versus Inhaled Nitric Oxide in Adult Respiratory Distress Syndrome,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 1996, 154(6 Pt 1):1671-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/22/359/abstract-text/8970353/pubmed\" id=\"8970353\" target=\"_blank\">",
"        8970353",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9411 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-9A95019A57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_359=[""].join("\n");
var outline_f0_22_359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165855\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165856\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165879\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165858\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521393\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165859\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822433\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822434\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165839\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165823\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233737\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165841\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165885\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165840\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7730063\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174529\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165877\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165844\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165827\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299275\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165832\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165834\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521390\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165861\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323130\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165836\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038611\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165826\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165843\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9411\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9411|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/61/20436?source=related_link\">",
"      Epoprostenol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/63/22519?source=related_link\">",
"      Epoprostenol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_22_360="Pulmonary alveolar proteinosis in children";
var content_f0_22_360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary alveolar proteinosis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/22/360/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/360/contributors\">",
"     Okan Elidemir, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/360/contributors\">",
"     Leland L Fan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/22/360/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/360/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/22/360/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/360/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/22/360/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary alveolar proteinosis (PAP) was first described in 1958 as an uncommon disorder in adults characterized by the accumulation of lipoproteinaceous material within alveoli [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/1\">",
"     1",
"    </a>",
"    ]. The prognosis was highly variable, and for over three decades the pathophysiology and treatment of this disease remained a mystery. With recent developments in molecular genetics, our understanding of the pathogenesis of PAP has improved significantly. At the same time, there were case reports of atypical forms of PAP arising in infants and children. Today there is mounting evidence that most cases of pediatric PAP result from a genetic or acquired defect in surfactant metabolism, leading to excessive accumulation of this material in air spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, clinical features, and treatment of pulmonary alveolar proteinosis in infants and children are discussed in this topic review. PAP in adults has different causes and clinical manifestations, and is discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four forms of PAP are recognized in children: congenital, acquired, secondary, and idiopathic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Congenital form",
"    </span>",
"    &nbsp;&mdash;&nbsp;The congenital form of PAP, also known as congenital alveolar proteinosis (CAP), includes inborn errors of surfactant metabolism, and lysinuric protein intolerance, and mutations in the components of the GM-CSF receptor.",
"   </p>",
"   <p>",
"    It is now recognized that the histopathologic manifestations of the congenital form are different from the autoimmune (classic) form of PAP. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Histopathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Inborn errors of surfactant metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic surfactant dysfunction disorders are caused by mutations in genes encoding proteins critical for the production and function of pulmonary surfactant. These rare disorders may produce familial or sporadic lung disease, with clinical presentations ranging from neonatal respiratory failure to childhood- or adult-onset interstitial lung disease. An overview of these disorders is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef71981 \" href=\"UTD.htm?15/47/16125\">",
"     table 1",
"    </a>",
"    ). They are discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=see_link\">",
"     \"Genetic disorders of surfactant dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Surfactant protein B",
"      </strong>",
"      &ndash; Surfactant protein B (SFTPB) is a hydrophobic protein involved with intracellular lamellar body formation and interaction with surfactant lipids to facilitate adsorption to the air-liquid interface. Neonates usually present at term with severe respiratory failure in the first hours to days of life that is unresponsive to exogenous surfactant, corticosteroids, and aggressive supportive intervention. Some patients have a milder initial presentation but ultimately develop respiratory failure leading to death [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=see_link&amp;anchor=H11110481#H11110481\">",
"       \"Genetic disorders of surfactant dysfunction\", section on 'SFTPB mutations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=see_link&amp;anchor=H16526774#H16526774\">",
"       \"Genetic disorders of surfactant dysfunction\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Surfactant protein C",
"      </strong>",
"      &ndash; Surfactant protein C (SFTPC) is a hydrophobic protein that also interacts with surfactant lipids to facilitate adsorption to the air-liquid interface. In contrast to SFTPB deficiency, SFTPC deficiency is an autosomal dominant disorder with variable age of onset and disease severity. Although some patients present early with respiratory failure, many have more insidious and later onset and prolonged survival [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/4\">",
"       4",
"      </a>",
"      ]. SFTPC mutations have been found in adults with familial interstitial lung disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=see_link&amp;anchor=H11110496#H11110496\">",
"       \"Genetic disorders of surfactant dysfunction\", section on 'SFTPC mutations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=see_link&amp;anchor=H16526774#H16526774\">",
"       \"Genetic disorders of surfactant dysfunction\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition to PAP, the histologic phenotypes of this condition include desquamative interstitial pneumonia (DIP) and chronic pneumonitis of infancy (CPI) in young children, and nonspecific interstitial pneumonia (NSIP) and usual interstitial pneumonia in older children and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/2,5\">",
"       2,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=see_link\">",
"       \"Classification of interstitial lung disease in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       ABCA3 mutations",
"      </strong>",
"      &ndash; ABCA3 is a member of the ATP binding cassette protein family, which are transmembrane proteins that transport substances across biologic membranes. Patients with ABCA3 mutations present as fatal respiratory failure of newborns, similar to SFTPB defects, as well as more indolent interstitial lung disease, presenting in infancy, childhood, or adulthood, similar to SFTPC defects. As in SFTPC defects, the histologic phenotypes include PAP as well as other pathologic patterns [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/2,6,7\">",
"       2,6,7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=see_link&amp;anchor=H11110552#H11110552\">",
"       \"Genetic disorders of surfactant dysfunction\", section on 'ABCA3 mutations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       NKX2.1 mutations",
"      </strong>",
"      &ndash; NKX2.1 (also called thyroid transcription factor-1, TTF1), is a homeodomain-containing transcription factor which activates the expression of select genes in the thyroid, lung, and some regions of the brain [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/8\">",
"       8",
"      </a>",
"      ]. NKX2.1 modulates expression of surfactant protein A (SFTPA), SFTPB, SFTPC, Clara cell secretory protein, and ABCA3. Mutations in NXX2.1 also cause hypothyroidism and chorea. About half of affected individuals have lung disease, and 20 percent have severe chronic interstitial lung disease [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/9\">",
"       9",
"      </a>",
"      ]. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=see_link&amp;anchor=H11110608#H11110608\">",
"       \"Genetic disorders of surfactant dysfunction\", section on 'NKX2.1 mutations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=see_link&amp;anchor=H16526774#H16526774\">",
"       \"Genetic disorders of surfactant dysfunction\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Lysinuric protein intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lysinuric protein intolerance (LPI) is an autosomal recessive disorder caused by defective plasma membrane transport of the cationic amino acids, lysine, arginine, and ornithine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/10\">",
"     10",
"    </a>",
"    ]. LPI results from a mutation in the SLC7A7 gene, encoding for the light chain of the cationic amino acid transporter y+ [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of LPI include failure to thrive, anorexia, vomiting, diarrhea, lethargy, and coma. Abnormalities of the liver, spleen, pancreas, kidney, bone marrow, and brain may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/12\">",
"     12",
"    </a>",
"    ]. Not all children with LPI develop PAP. Children with LPI who develop PAP often die, and recurrence of PAP following heart-lung transplantation has been reported with fatal consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19978715\">",
"    <span class=\"h3\">",
"     GM-CSF receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor affect surfactant catabolism and appear to be a rare cause of PAP in children. &nbsp;",
"   </p>",
"   <p>",
"    Alveolar proteinosis has been observed in mice deficient in the beta chain that is common to the",
"    <span class=\"nowrap\">",
"     GM-CSF/IL-3/IL-5",
"    </span>",
"    receptor common beta chain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/13\">",
"     13",
"    </a>",
"    ]; failure of beta chain expression has also been found in four of eight children with PAP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/14\">",
"     14",
"    </a>",
"    ]. A homozygous mutation in the beta chain of the GM-CSF receptor (CSF2RB) was reported in a child who presented at nine years of age with bilateral pneumonia followed by progressive dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/15\">",
"     15",
"    </a>",
"    ]. Radiographic findings, elevated levels of GM-CSF, and histopathology were consistent with PAP. Previously identified point mutations in the beta chain probably represented sequence polymorphisms and were not associated with pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, three female children with PAP have been reported with mutations in the gene encoding the ligand-binding alpha chain of the GM-CSF receptor (CSF2RA) located in the X-Y pseudoautosomal region (PAR1) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. These patients presented in early or mid childhood with respiratory distress and elevated levels of GM-CSF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acquired form",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, and occasionally in older children and adolescents, PAP is usually an autoimmune disease; antibodies to granulocyte macrophage colony-stimulating factor (anti-GM-CSF) are present in 90 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autoimmune PAP with anti-GM-CSF antibodies has been reported in only a few children, who presented in late childhood or adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Thus, unlike adults with PAP, it appears that the majority of infants and children with PAP do not have the autoimmune form of the disease. As an example, in a study of 15 children with PAP, none had anti-GM-CSF antibodies in the serum, and only one had anti-GM-CSF antibodies in bronchoalveolar lavage fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Secondary form",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in adults, acquired PAP in children can be seen with the following three categories of disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/24\">",
"     24",
"    </a>",
"    ]: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections (eg, Nocardia asteroides, Mycobacterium tuberculosis, Mycobacterium avium-intracellulare, Pneumocystis jirovecii, HIV)",
"     </li>",
"     <li>",
"      Hematologic malignancies (lymphoma, leukemia) and immune deficiencies (HIV infection, severe combined immunodeficiency)",
"     </li>",
"     <li>",
"      Exposure to inhaled chemicals (insecticides, fumes) and minerals (silica, aluminum and titanium)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Idiopathic form",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the recent discoveries described above, the etiology of PAP in some infants and children is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/23\">",
"     23",
"    </a>",
"    ]. In about one-third of infants with pathologic features suggesting a surfactant defect (interstitial expansion, type II epithelial cell hyperplasia and limited lipoproteinaceous material in the alveolar spaces), no surfactant mutations have been identified. Thus, it is likely that many of these children have defects in intracellular surfactant metabolism that have yet to be discovered. Because most older children with PAP do not have anti-GM-CSF antibodies, the etiology in these patients remains unknown. It is possible that some of these children have mutations in CSF2RA, as pediatric patients with idiopathic PAP were reported prior to the discovery of this mutation. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Inborn errors of surfactant metabolism'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic histopathologic characteristic of classic autoimmune PAP is the accumulation of granular, periodic acid-Schiff (PAS) positive, lipoproteinaceous material within the alveoli [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. The alveolar septae usually display neither fibrosis nor inflammatory reaction, but hyperplastic type II pneumocytes may be seen, particularly in patients with inborn errors of surfactant metabolism. Large macrophages filled with PAS positive material are commonly seen in the air spaces.",
"   </p>",
"   <p>",
"    It is now recognized that the histopathologic manifestations of the congenital form are different from the autoimmune (classic) form of PAP that is usually seen in adults. The most prominent histopathologic feature is interstitial widening; type II alveolar cell hyperplasia, and the presence of cholesterol clefts, are also features of CAP but not of autoimmune PAP. Accumulation of lipoproteinaceous material in the alveolar spaces (alveolar proteinosis) is also seen but this is less prominent than in the acquired form of PAP.",
"   </p>",
"   <p>",
"    Electron microscopic (EM) evaluation of the material filling the air spaces and vacuoles of the alveolar macrophages reveals lamellar bodies and tubular myelin, characteristic of surfactant [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. In SFTPB mutations, EM evaluation shows disorganized lamellar bodies, and in ABCA3 mutations, EM evaluation reveals characteristically abnormal lamellar bodies that are smaller and denser with a peripheral dense inclusion, usually within the type II epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/2\">",
"     2",
"    </a>",
"    ]. The lamellar bodies in SFPTC are normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the congenital forms of PAP, the clinical presentation can range from severe respiratory failure in the neonatal period to more insidious symptoms of chronic interstitial lung disease in older children, including dyspnea, exercise intolerance, cough, and poor growth or weight loss.",
"   </p>",
"   <p>",
"    In infants and younger children with the other forms of PAP, decreased activity may be the initial symptom. Weight loss or failure to gain weight is common. A mild, nonproductive cough may be present. Hypoxemia is typically noted.",
"   </p>",
"   <p>",
"    The primary presenting symptom in older children and adults is shortness of breath, usually with exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Mild cough, usually nonproductive but occasionally with white sputum, may be reported, especially in older children and adolescents. Chest pain and hemoptysis are rare. Fever usually indicates a superinfection or a different disease. The physical examination may reveal nonspecific manifestations of pulmonary disease, including tachypnea, cyanosis, digital clubbing and fine crackles. PAP is characterized by a significant discordance between the auscultatory findings, which are minimal, and the radiographic findings, which include extensive infiltrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs of adults with acquired PAP typically show bilateral alveolar filling pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The infiltrates are often more prominent in the perihilar regions, resembling the \"butterfly\" or \"bat wing\" appearance of pulmonary edema, but without cardiomegaly.",
"   </p>",
"   <p>",
"    The radiographic features of infants and children with congenital PAP are more diffuse and are typical of interstitial lung disease. Chest films typically show ground-glass densities and increased interstitial markings.",
"   </p>",
"   <p>",
"    High resolution computerized tomography (HRCT) scanning typically shows ground-glass opacities of alveolar spaces and thickening of the interlobular and intralobular septa, with no architectural distortion, in typical polygonal shapes called \"crazy paving\" [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common abnormalities in pulmonary function tests (PFTs) are a mild restrictive pattern and a reduction in the diffusing capacity for carbon monoxide [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/25\">",
"     25",
"    </a>",
"    ]. The arterial PO2 and oxygen saturation values are generally low, with a low PCO2 and normal pH. Alveolar-arterial PO2 difference is high, and the shunt fraction, while breathing 100 percent oxygen, typically is elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation of PAP in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inborn errors in surfactant metabolism can have important genetic implications for the family. Therefore, clinicians should consider specific testing for these disorders in infants or children with any of the following clinical features. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Laboratory tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe unexplained lung disease in the newborn period",
"     </li>",
"     <li>",
"      Diffuse disease involving the entire lung on high-resolution computerized tomography (HRCT)",
"     </li>",
"     <li>",
"      Histopathology that demonstrates findings of congenital alveolar proteinosis (CAP), desquamative interstitial pneumonia (DIP), nonspecific interstitial pneumonia (NSIP), or chronic pneumonitis of infancy (CPI) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=see_link\">",
"       \"Classification of interstitial lung disease in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Electron microscopy demonstrating abnormal or absent lamellar bodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In older children, the diagnosis of PAP is usually raised during the course of an evaluation for the nonspecific clinical symptoms described above. The diagnosis is suggested by radiographic findings, and confirmed by bronchoscopy, ideally with transbronchial or open lung biopsy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Bronchoscopy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Lung biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing for SFTPB, SFTPC, ABCA3 is required to definitively diagnose an inborn error of surfactant metabolism. Some patients with ABCA3 deficiency may not be successfully diagnosed by current methods for genetic testing, necessitating open lung biopsy in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/28\">",
"     28",
"    </a>",
"    ]. Testing for CSF2RA and CSF2RB mutations should be included, if available. Testing for SLC7A7 mutations is necessary to detect lysinuric protein intolerance. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Congenital form'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the noncongenital forms of PAP, routine laboratory tests are usually normal other than an elevation in serum lactate dehydrogenase concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in adults, children with a clinical picture consistent with autoimmune PAP should be tested for anti-GM-CSF antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with the noncongenital forms of PAP, bronchoalveolar lavage (BAL) typically yields a milky effluent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/27\">",
"     27",
"    </a>",
"    ]. Examination of the sediment using light microscopy reveals large amounts of amorphous, lipoproteinaceous material that stains brightly positive with PAS; large macrophages may also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/1,24,25\">",
"     1,24,25",
"    </a>",
"    ]. The differential cell count of BAL fluid shows macrophage predominance without inflammatory cells. Electron microscopy is not routinely needed for diagnosis but can be helpful in validating the light microscopy findings.",
"   </p>",
"   <p>",
"    Although diagnosis of noncongenital PAP can be made based on clinical presentation and HRCT and BAL findings, histologic confirmation is often required. Studies in adults show that transbronchial biopsies are as reliable as open lung biopsies in establishing the diagnosis of PAP and should be utilized more often [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/24\">",
"     24",
"    </a>",
"    ]. The diagnostic findings of PAP are accumulation of PAS positive, lipoproteinaceous material in air spaces of otherwise preserved lung tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although genetic testing is the gold standard for the diagnosis of the congenital forms of PAP, lung biopsy can be useful in certain circumstances. In the neonate with respiratory failure, genetic testing that takes up to four weeks may delay timely diagnosis and referral for lung transplantation. In this case, lung biopsy can be virtually diagnostic of an inborn error of surfactant metabolism, especially if abnormal lamellar bodies are demonstrated. Also, some children have a lung biopsy consistent with an inborn error of surfactant metabolism, but no mutations are found. This suggests that there are mutations in other genes associated with surfactant metabolism that have yet to be discovered. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Idiopathic form'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates with SFTPB or ABCA3 mutations usually require mechanical ventilation for severe respiratory failure and are sometimes treated with extracorporeal membrane oxygenation because early diagnosis is difficult (lung biopsy is often deferred due to the severity of illness and genetic testing takes time). In general, these interventions are futile. Treatment with corticosteroids, exogenous surfactant therapy, and whole lung lavage are also ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/29\">",
"     29",
"    </a>",
"    ]. Lung transplantation is the only treatment that appears to improve outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/30\">",
"     30",
"    </a>",
"    ]. There is no established treatment for NKX2.1 mutations, although lung transplantation is theoretically possible.",
"   </p>",
"   <p>",
"    Treatment of LPI consists of protein-restricted diet and supplementation with oral citrulline. Transplantation is contraindicated for children with LPI and end-stage lung disease as fatal recurrence in the transplanted lung has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infants and older children",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Anti-inflammatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants and older children with SFTPC and ABCA3 mutations, anti-inflammatory therapy (eg, corticosteroids and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/31\">",
"     31",
"    </a>",
"    ] are suggested despite the lack of clinical trials. The rationale for treatment is that abnormal protein folding as a result of these mutations leads to protein degradation within the endoplasmic reticulum and release of toxic mediators. Despite therapy, the disease is often slowly progressive and may ultimately require lung transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Whole lung lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large volume lung lavage with saline has been the traditional choice of treatment for acquired, secondary, and idiopathic PAP for many years, and is recommended for children and adults with these variants of PAP and with moderate to severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/25-27,32,33\">",
"     25-27,32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and treatment of pulmonary alveolar proteinosis in adults\", section on 'Whole lung lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In older children and adults, a double lumen endotracheal tube is used to ventilate one lung while lavaging the other. In young children, the small caliber of the airway poses a major obstacle. In some of these cases, partial or whole lung lavage has been accomplished using standard endotracheal tube intubation and hyperbaric oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/34\">",
"     34",
"    </a>",
"    ] and combined intubation and flexible bronchoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/27\">",
"     27",
"    </a>",
"    ]. In other cases, lavage has been successfully performed during extracorporeal oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/26,32,33\">",
"     26,32,33",
"    </a>",
"    ]. In general, the objective is to lavage repeatedly until the recovered fluid contains little sedimentable material [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/32\">",
"     32",
"    </a>",
"    ]. Improvement of clinical symptoms and arterial PO2 is usually achieved within a few days. Resolution of pulmonary infiltrates on chest radiographs or CT scans may take longer.",
"   </p>",
"   <p>",
"    Because spontaneous resolution of PAP has been reported in some patients and there are no controlled studies evaluating the effectiveness of pulmonary lavage, this therapy has not been universally recommended. Many authors advocate massive pulmonary lavages only for children suffering from respiratory distress or the debilitating effects of the disease (ie, exercise intolerance, poor growth, and pulmonary hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/25-27,32,33\">",
"     25-27,32,33",
"    </a>",
"    ]. Some children and adults with PAP experience long-term resolution of the disease after one or more whole lung lavages [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Recombinant GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because reduced GM-CSF function is thought to play a role in some forms of PAP, some adults with secondary PAP have been treated with recombinant GM-CSF, given subcutaneously or as an aerosol, with some success. This therapy has also been used in some children with acquired PAP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and treatment of pulmonary alveolar proteinosis in adults\", section on 'Granulocyte macrophage-colony stimulating factor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SFTPB or ABCA3 mutations in neonates with respiratory failure are usually fatal without lung transplantation. SFTPC or ABCA3 mutations in older children are most often associated with chronic interstitial lung disease, which is slowly progressive and may ultimately also require lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/2\">",
"     2",
"    </a>",
"    ]. Other individuals probably have stable chronic lung disease and acceptable quality of life.",
"   </p>",
"   <p>",
"    As in adults, acquired, secondary, or idiopathic PAP carries a variable prognosis in children. Spontaneous remission or long-term resolution of symptoms after a single lavage has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/25,33,35\">",
"     25,33,35",
"    </a>",
"    ]. Some patients may require repeated lavages, as often as twice a year. Deterioration of respiratory status despite repeated lavages may occur, resulting in death [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/360/abstract/25-27,32\">",
"     25-27,32",
"    </a>",
"    ]. Recurrence of PAP has been reported after lung transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis and treatment of pulmonary alveolar proteinosis in adults\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary alveolar proteinosis (PAP) is an uncommon disorder characterized by the accumulation of lipoproteinaceous material within alveoli. Four forms of PAP are recognized in children: congenital, acquired, secondary, and idiopathic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The congenital form of PAP is usually caused by inborn errors of surfactant metabolism or by a defect in the plasma membrane transport of cationic amino acids (known as lysinuric protein intolerance, LPI). The clinical presentation can range from severe respiratory failure in the neonatal period to more insidious symptoms of chronic interstitial lung disease in older children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Congenital form'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired PAP is an autoimmune disease mediated by anti-GM-CSF antibodies. This form accounts for almost all cases of PAP in adults but is rare in children. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Acquired form'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital PAP should be suspected in patients presenting with severe unexplained lung disease in the newborn period, or infants and children with diffuse disease involving the entire lung on high-resolution computerized tomography (HRCT). These patients should be tested for an inborn error of surfactant metabolism (SFTPB, SFTPC, ABCA3 and NKX2.1), as well as for SLC7A7, CSF2RA, and CSF2RB mutations to detect lysinuric protein intolerance and mutations of the GM-CSF receptor, respectively. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In older children, the diagnosis of PAP is usually raised during the course of an evaluation for nonspecific symptoms and signs of pulmonary disease. The diagnosis is suggested by radiographic findings, and confirmed by bronchoscopy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lung biopsy. These children should also be tested for anti-GM-CSF antibodies to evaluate for acquired PAP, although this form is rare in children. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For neonates with severe congenital PAP, lung transplantation is the only treatment that appears to improve outcome. Prolonged mechanical ventilation, extracorporeal membrane oxygenation, and treatment with corticosteroids, exogenous surfactant therapy, or whole lung lavage are ineffective. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Neonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For older children and adolescents with moderate to severe symptoms of acquired, secondary, and idiopathic PAP, we suggest whole lung lavage (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Whole lung lavage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/1\">",
"      ROSEN SH, CASTLEMAN B, LIEBOW AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/2\">",
"      Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant proteins. Neonatology 2007; 91:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/3\">",
"      Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993; 328:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/4\">",
"      Thouvenin G, Abou Taam R, Flamein F, et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/5\">",
"      Nogee LM, Dunbar AE 3rd, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/6\">",
"      Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004; 350:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/7\">",
"      Doan ML, Guillerman RP, Dishop MK, et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/8\">",
"      Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond) 2009; 116:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/9\">",
"      Carr&eacute; A, Szinnai G, Castanet M, et al. Five new TTF1/NKX2.1 mutations in brain-lung-thyroid syndrome: rescue by PAX8 synergism in one case. Hum Mol Genet 2009; 18:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/10\">",
"      Santamaria F, Parenti G, Guidi G, et al. Early detection of lung involvement in lysinuric protein intolerance: role of high-resolution computed tomography and radioisotopic methods. Am J Respir Crit Care Med 1996; 153:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/11\">",
"      Santamaria F, Brancaccio G, Parenti G, et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr 2004; 145:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/12\">",
"      Parenti G, Sebastio G, Strisciuglio P, et al. Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course. J Pediatr 1995; 126:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/13\">",
"      Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995; 2:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/14\">",
"      Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/15\">",
"      Suzuki T, Maranda B, Sakagami T, et al. Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur Respir J 2011; 37:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/16\">",
"      Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008; 205:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/17\">",
"      Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008; 205:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/18\">",
"      Notarangelo LD, Pessach I. Out of breath: GM-CSFRalpha mutations disrupt surfactant homeostasis. J Exp Med 2008; 205:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/19\">",
"      Suzuki T, Sakagami T, Young LR, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med 2010; 182:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/20\">",
"      Yamamoto H, Yamaguchi E, Agata H, et al. A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis. Pediatr Pulmonol 2008; 43:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/21\">",
"      Robinson TE, Trapnell BC, Goris ML, et al. Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis. Chest 2009; 135:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/22\">",
"      Price A, Manson D, Cutz E, Dell S. Pulmonary alveolar proteinosis associated with anti-GM-CSF antibodies in a child: successful treatment with inhaled GM-CSF. Pediatr Pulmonol 2006; 41:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/23\">",
"      Latzin P, Tredano M, W&uuml;st Y, et al. Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax 2005; 60:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/24\">",
"      Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest 1997; 111:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/25\">",
"      Mahut B, Delacourt C, Scheinmann P, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics 1996; 97:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/26\">",
"      Mazyck EM, Bonner JT, Herd HM, Symbas PN. Pulmonary lavage for childhood pulmonary alveolar proteinosis. J Pediatr 1972; 80:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/27\">",
"      Mahut B, de Blic J, Le Bourgeois M, et al. Partial and massive lung lavages in an infant with severe pulmonary alveolar proteinosis. Pediatr Pulmonol 1992; 13:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/28\">",
"      Gower WA, Wert SE, Ginsberg JS, et al. Fatal familial lung disease caused by ABCA3 deficiency without identified ABCA3 mutations. J Pediatr 2010; 157:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/29\">",
"      Hamvas A, Cole FS, deMello DE, et al. Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr 1994; 125:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/30\">",
"      Palomar LM, Nogee LM, Sweet SC, et al. Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. J Pediatr 2006; 149:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/31\">",
"      Rosen DM, Waltz DA. Hydroxychloroquine and surfactant protein C deficiency. N Engl J Med 2005; 352:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/32\">",
"      Hiratzka LF, Swan DM, Rose EF, Ahrens RC. Bilateral simultaneous lung lavage utilizing membrane oxygenator for pulmonary alveolar proteinosis in an 8-month-old infant. Ann Thorac Surg 1983; 35:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/33\">",
"      Seard C, Wasserman K, Benfield JR, et al. Simultaneous bilateral lung lavage (alveolar washing) using partial cardiopulmonary bypass. Am Rev Respir Dis 1970; 101:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/34\">",
"      Spock A. Long-term survival of paediatric patients with pulmonary alveolar proteinosis treated with lung lavage. Eur Respir J 2005; 25:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/360/abstract/35\">",
"      Paul K, M&uuml;ller KM, Oppermann HC, N&uuml;tzenadel W. Pulmonary alveolar lipoproteinosis in a seven-year-old girl. A follow-up over six years. Acta Paediatr Scand 1991; 80:477.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6351 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_360=[""].join("\n");
var outline_f0_22_360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Congenital form",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Inborn errors of surfactant metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Lysinuric protein intolerance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19978715\">",
"      - GM-CSF receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acquired form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Secondary form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Idiopathic form",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infants and older children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Anti-inflammatory therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Whole lung lavage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Recombinant GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6351|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/47/16125\" title=\"table 1\">",
"      Genetic disorders surfactant dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=related_link\">",
"      Classification of interstitial lung disease in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=related_link\">",
"      Diagnosis and treatment of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=related_link\">",
"      Genetic disorders of surfactant dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_22_361="Overview of atrial fibrillation";
var content_f0_22_361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/22/361/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/361/contributors\">",
"     Alan Cheng, MD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/361/contributors\">",
"     Kapil Kumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/22/361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/361/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/22/361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/361/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/22/361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is the most common cardiac arrhythmia that has the following electrocardiographic characteristics (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link&amp;anchor=H3660804#H3660804\">",
"     \"The electrocardiogram in atrial fibrillation\", section on 'Common findings'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The RR intervals follow no repetitive pattern&mdash;they have been labeled as &ldquo;irregularly irregular.&rdquo;",
"     </li>",
"     <li>",
"      While electrical activity suggestive of P waves is seen in some leads, there are no distinct P waves. Thus, even when an atrial cycle length (the interval between two atrial activations or the P-P interval) can be defined, it is not regular and often less than 200 milliseconds (translating to an atrial rate greater than 300 beats per minute).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AF can have adverse consequences related to a reduction in cardiac output and to atrial and atrial appendage thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In addition affected patients may be at increased risk for mortality. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Long-term outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    AF is more prevalent in men and with increasing age (",
"    <a class=\"graphic graphic_figure graphicRef82929 \" href=\"UTD.htm?33/19/34098\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide a broad overview of AF, including the management of the patient. The reader will be referred to more detailed discussions when appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440859983\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive heart disease and coronary heart disease (CHD) are the most common underlying disorders in patients with AF in developed countries. Rheumatic heart disease, although now uncommon in developed countries, is associated with a much higher incidence of AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Disease associations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440860004\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irrespective of the underlying risk factor(s), changes in the electrophysiology of the atrial myocardium are likely important. The pathophysiology of AF is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=see_link&amp;anchor=H186294596#H186294596\">",
"     \"Mechanisms of atrial fibrillation\", section on 'Basic atrial electrophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541379272\">",
"    <span class=\"h2\">",
"     General classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the terms acute and chronic AF were used to describe the temporal nature of a patient&rsquo;s AF. These two terms have been replaced with the following classification schema proposed by the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association and the European Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA,",
"    </span>",
"    ESC) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First detected or diagnosed AF, independent of the duration of AF or the presence or absence of symptoms.",
"     </li>",
"     <li>",
"      Paroxysmal (ie, self-terminating or intermittent) AF &mdash; Paroxysmal AF is defined as recurrent AF (&ge;2 episodes) that terminates spontaneously in seven days or less, usually less than 24 hours. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=see_link\">",
"       \"Paroxysmal atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent AF &mdash; Persistent AF is defined as AF that fails to self-terminate within seven days. Episodes often require pharmacologic or electrical cardioversion to restore sinus rhythm. While a patient who has had persistent AF can have later episodes of paroxysmal AF, AF is generally considered a progressive disease. In individuals with paroxysmal AF, progression to persistent and permanent AF occur in &gt;50 percent beyond 10 years despite antiarrhythmic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long-standing persistent AF, which refers to persistent AF that has lasted for one year or more [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Permanent AF &mdash; Permanent AF is a term used to identify individuals with persistent atrial fibrillation where a decision has been made to no longer pursue a rhythm control strategy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This classification applies to recurrent episodes of AF that last more than 30 seconds and that are unrelated to a reversible cause. If the AF is secondary to cardiac surgery, pericarditis, myocardial infarction (MI), hyperthyroidism, pulmonary embolism, pulmonary disease, or other reversible causes, therapy is directed toward the underlying disease as well as the AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439358969\">",
"    <span class=\"h2\">",
"     Lone AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term lone AF is less often used than in the past and was not included in the",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines discussed above. Lone AF has generally referred to patients with paroxysmal, persistent, or permanent AF who have no structural heart disease. It has primarily been applied to patients &le;60 years of age and identifies a group of individuals at lowest risk of complications associated with AF, including embolization. By definition, such patients have a CHADS2 score of &ldquo;0&rdquo; (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'CHADS2 score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are characteristics of this low-risk population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depending in part upon the population studied and the definition used, lone AF accounts for less than 15 to as many as 30 percent of cases of permanent AF [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/11-14\">",
"       11-14",
"      </a>",
"      ] and 25 to 45 percent of cases of paroxysmal AF [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=see_link\">",
"       \"Paroxysmal atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Affected patients are younger than those with structural heart disease and are often male [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/11,17-21\">",
"       11,17-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with lone AF are often symptomatic and associate certain triggers with episodes of AF. In a series of 181 patients (94 percent of whom had paroxysmal AF), the following triggers were reported (percent): sleeping (44), exercise (36), alcohol (36), eating (34) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/22\">",
"       22",
"      </a>",
"      ]. Patients with exercise-related AF could have it as a consequence of high catechol levels during exercise or during the period of high vagal tone after exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Familial aggregation in lone AF is common, as demonstrated in the following two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 110 individuals with lone AF, a family history of AF was present in up to 38 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using Danish national registers, over 9000 individuals with lone AF were identified. The incidence rate ratios (IRR) for lone AF given an affected first- or second-degree relative were significantly increased at 3.48 and 1.64, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/24\">",
"       24",
"      </a>",
"      ]. For individuals less than 40 years of age with an affected first-degree with age onset also less than 40 years, the IRR was 5.42.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23782624\">",
"    <span class=\"h2\">",
"     Recurrent AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous monitoring studies have shown that approximately 90 percent of patients have recurrent episodes of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/25\">",
"     25",
"    </a>",
"    ]. However, up to 90 percent of episodes are not recognized by the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/26\">",
"     26",
"    </a>",
"    ], and asymptomatic episodes lasting more than 48 hours are not uncommon, occurring in 17 percent of patients in a report using continuous monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/25\">",
"     25",
"    </a>",
"    ]. The latter study also showed that 40 percent of patients had episodes of AF-like symptoms in the absence of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=see_link\">",
"     \"Paroxysmal atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122239619\">",
"    <span class=\"h2\">",
"     Subclinical AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical AF, which is a term that is used uncommonly by cardiologists who specialize in arrhythmias, is defined as AF detected (with any monitoring technique) in asymptomatic individuals without a prior diagnosis. Most of these individuals will have PAF. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between subclinical AF and cryptogenic stroke is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link&amp;anchor=H19246582#H19246582\">",
"     \"Cryptogenic stroke\", section on 'Subclinical atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, physical examination, and specific laboratory and cardiologic testing are all part of the evaluation of the patient with AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with AF are symptomatic. Among those that are, symptoms associated with AF are variable and the history should focus on obtaining the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A description of the symptoms: onset or date of discovery, the frequency and duration, severity, and qualitative characteristics.",
"      <br/>",
"      <br/>",
"      Typical symptoms include palpitations, tachycardia, fatigue, weakness, dizziness, lightheadedness, reduced exercise capacity, increased urination, or mild dyspnea. More severe symptoms include dyspnea at rest, angina, presyncope, or infrequently, syncope. In addition, some patients present with an embolic event or the insidious onset of right-sided heart failure (as manifested by peripheral edema, weight gain, and ascites).",
"     </li>",
"     <li>",
"      Precipitating causes: exercise, emotion, or alcohol.",
"     </li>",
"     <li>",
"      The presence of the following disease associations: cardiovascular or cerebrovascular disease, diabetes, hypertension, chronic obstructive pulmonary disease, or potentially reversible causes (eg, hyperthyroidism, excessive alcohol ingestion). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A complete examination of the cardiovascular system should be performed in all individuals with newly diagnosed AF and in those with a change in symptom status. Abnormal findings may inform health care providers about either contributing factors for (eg, murmur of mitral stenosis) or the impact of (eg, evidence of heart failure) AF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"       \"Examination of the precordial pulsation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link\">",
"       \"Examination of the arterial pulse\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) is used to verify the presence of AF and is necessary to make the diagnosis. There are a number of potential pitfalls in the electrocardiographic diagnosis of AF. Errors in the diagnosis of AF are especially common with computerized ECG interpretation and in patients who are continuously or intermittently paced. Hence, it is important that the ECG rhythm reported automatically by the machine is interpreted by a skilled reader. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link&amp;anchor=H3#H3\">",
"     \"The electrocardiogram in atrial fibrillation\", section on 'Difficulties in diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ECG should also be evaluated for the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Markers of nonelectrical cardiac disease, such as left ventricular hypertrophy (possible hypertension) or Q waves (possible coronary artery disease)",
"     </li>",
"     <li>",
"      Markers of electrical heart disease, such as delta wave or short PR interval (preexcitation) or bundle branch block (conduction system disease)",
"     </li>",
"     <li>",
"      The QT interval (to identify the potential risk of antiarrhythmic therapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transthoracic echocardiogram (TTE) is performed to evaluate the size of the right and left atria and the size and function of the right and left ventricles; to detect possible valvular heart disease, left ventricular hypertrophy, and pericardial disease; and to assess peak right ventricular pressure.",
"   </p>",
"   <p>",
"    The TTE may also identify left atrial thrombus, although the sensitivity is low. Transesophageal echocardiography is much more sensitive for identifying thrombi in the left atrium or left atrial appendage and can be used to determine the need for three to four weeks of anticoagulation prior to any attempt at pharmacologic or electrical cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23782659\">",
"     'Prevention of systemic embolization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Additional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing is reasonable for patients with signs or symptoms of ischemic heart disease. It is also useful to help guide pharmacotherapy for AF as some antiarrhythmic medications are contraindicated in patients with coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H523850628#H523850628\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Selecting an antiarrhythmic drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Holter monitoring or event recorders are used to identify the arrhythmia if it is intermittent and not captured on routine electrocardiography and assess overall ventricular response rates, especially in individuals where a rate control strategy has been chosen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical or subclinical hyperthyroidism is present in less than 5 percent of patients with AF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/27\">",
"     27",
"    </a>",
"    ]. A thyroid-stimulating hormone (TSH) should be obtained in all patients with a first episode of AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other important baseline tests include a complete blood count, a serum creatinine, an analysis for proteinuria, and a test for diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care providers are presented with two broad types of patients with AF: those with newly diagnosed AF and those who have been previously diagnosed and managed. Care of the former includes decisions regarding the need for anticoagulation and the choice between rate or rhythm control strategies. For patients with established diagnosis, periodic assessment of the adequacy of treatment is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440860093\">",
"    <span class=\"h2\">",
"     New onset AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with new onset (ie, first detected or diagnosed) AF present with symptoms related to the arrhythmia (see",
"    <a class=\"local\" href=\"#H4\">",
"     'History and physical examination'",
"    </a>",
"    above). Except for embolization, the symptoms associated with new onset AF are primarily due to a rapid ventricular response. Thus, many patients have dramatic improvement in their sense of well being when the ventricular rate is slowed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of new onset atrial fibrillation\", section on 'Initial rate control with mild to moderate symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two broad management issues that must be addressed early in patients with new onset AF: the prevention of systemic embolization and the choice between a rhythm or rate control strategy, both of which improve symptoms. These issues will be addressed briefly here. More detailed discussions are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23782659\">",
"    <span class=\"h3\">",
"     Prevention of systemic embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every patient with AF should be evaluated for the need of antithrombotic therapy to prevent systemic embolization. This has traditionally been accomplished by the application of the CHADS2 risk score (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ). Modifications of this scoring system have resulted in the CHA2DS2-VASc score (",
"    <a class=\"graphic graphic_table graphicRef83272 \" href=\"UTD.htm?30/23/31101\">",
"     table 2",
"    </a>",
"    ), which is gaining wider acceptance. Patients who may require antithrombotic therapy include those in whom cardioversion to sinus rhythm is being considered (short-term anticoagulation) and those who meet criteria for chronic anticoagulation. All patients whose risk of embolization exceeds the risk of bleeding are candidates for long-term antithrombotic therapy. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356406633\">",
"    <span class=\"h3\">",
"     Rate versus rhythm control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who present with AF will require slowing of the ventricular rate to improve symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once sinus rhythm is achieved, a decision regarding the long-term approach to the management of the rhythm disturbance (rhythm versus rate control) should be made. A rhythm control strategy uses either antiarrhythmic drug therapy, percutaneous catheter ablation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a surgical procedure. Electrical cardioversion may be necessary prior to an attempt to maintain sinus rhythm. Rate slowing drugs are generally started before rhythm control and continued in many patients who remain in sinus rhythm (in the event of return to AF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H5#H5\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'Pulmonary vein isolation procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\", section on 'Maze operation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rate control strategy generally uses drugs that slow conduction across the atrioventricular (AV) node, such as beta blockers, non-dihydropyridine calcium channel blockers, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H5421069#H5421069\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Definitions'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Current data suggest that rhythm and rate control strategies are associated with similar rates of mortality and serious morbidity, such as embolic risk. In addition, assessments of quality of life have not shown significant differences between the two in many studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H8#H8\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Comparative studies'",
"    </a>",
"    .).",
"    <br/>",
"    <br/>",
"    The decision to adopt a rhythm or rate control strategy is often dictated by the (1) presence of symptoms associated with atrial fibrillation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    (2) presence of diminutions in left ventricular systolic function thought secondary to the arrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H16#H16\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Preference for rate control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H17#H17\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Preference for rhythm control'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The methods to achieve either rate or rhythm control are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link\">",
"     \"Management of new onset atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356406975\">",
"    <span class=\"h3\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with AF may require care at an acute-care facility or an inpatient unit of a hospital. Common indications for care at one or both of these facilities include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of heart failure or hypotension after control of the rate or rhythm",
"     </li>",
"     <li>",
"      Initiation of antiarrhythmic drug therapy",
"     </li>",
"     <li>",
"      Treatment of an associated medical problem, which is often the reason for the arrhythmia. Examples include the treatment of hypertension, infection, thyroid storm, exacerbation of chronic obstructive pulmonary disease (COPD), pulmonary embolism, persistent myocardial ischemia, or acute pericarditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other indications for hospitalization are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link&amp;anchor=H521214863#H521214863\">",
"     \"Management of new onset atrial fibrillation\", section on 'Indications for hospitalization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440860149\">",
"    <span class=\"h2\">",
"     Paroxysmal, persistent, longstanding persistent, or permanent AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with paroxysmal, persistent, longstanding persistent, or permanent AF will need periodic care as well as occasional urgent evaluation during the natural history of their disease. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest routine follow-up every twelve months in stable patients and sooner if there are changes in symptoms. Some of our experts see patients on high risk antiarrhythmic therapy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , every six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440860157\">",
"    <span class=\"h3\">",
"     Routine care",
"    </span>",
"    &nbsp;&mdash;&nbsp;From time to time, patients should be monitored for the following: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efficacy and safety of antithrombotic therapy (International normalized ratio for patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and creatinine clearance for patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H5#H5\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Antithrombotic prevention'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Functional status, including change in symptoms (history)",
"     </li>",
"     <li>",
"      Efficacy and safety of antiarrhythmic drug therapy (ECG, assessment of renal and hepatic function, and perhaps other tests) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Efficacy of rate control (history, ECG, and perhaps extended Holter monitoring) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440860182\">",
"    <span class=\"h3\">",
"     Urgent care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent care is necessary in patients who present with symptoms or signs of symptomatic AF. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'History and physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to evaluating the efficacy of rate or rhythm control, the health care provider many need to evaluate and manage changes in the symptoms and signs of coronary artery disease or heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the morbidity associated with AF, primarily heart failure and stroke, is well established, it is not clear if AF itself results in excess mortality. Patients under the age of 60 who have AF but no apparent heart disease have been considered a group with a good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/11,28\">",
"     11,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H439358969\">",
"     'Lone AF'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, AF appears to be a risk factor for increased mortality in otherwise healthy",
"    <strong>",
"     older",
"    </strong>",
"    individuals and those with coexisting cardiovascular disease, an effect that appears to be more prominent in women [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. This was illustrated in a report from the Framingham Heart Study in which 621 subjects between the ages of 55 and 94 who developed AF were compared to those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/29\">",
"     29",
"    </a>",
"    ]. AF almost doubled the risk of death in both men and women (",
"    <a class=\"graphic graphic_figure graphicRef71640 \" href=\"UTD.htm?11/13/11486\">",
"     figure 2",
"    </a>",
"    ). After adjustment for the preexisting cardiovascular diseases with which AF was associated, AF was still associated with a significantly increased risk of death (odds ratio 1.9 for women and 1.5 for men). Both heart failure (HF) and stroke contributed to the excess mortality.",
"   </p>",
"   <p>",
"    Two large observational studies have found an increased risk of death and cardiovascular events in",
"    <strong>",
"     younger",
"    </strong>",
"    adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 20-year follow-up of over 15,000 men and women between the ages of 45 and 64 in which 47 women and 53 men had AF on a single ECG at baseline, the presence of AF was associated with a marked increase in the risk of a cardiovascular event (death or hospitalization) (89 versus 27 percent in women and 66 versus 45 percent in men) and was a significant independent predictor of all-cause mortality (relative risk 2.2 in women and 1.5 in men) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in a post hoc analysis of the Women&rsquo;s Health Study of 34,772 women with a median age of 53 who were free of AF and cardiovascular disease at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/31\">",
"       31",
"      </a>",
"      ]. At a median follow-up of 15.4 years about three percent developed AF. New onset AF was associated with a significantly increased adjusted risk of all-cause, cardiovascular, and non-cardiovascular mortality (hazard ratios [HR] 2.14, 95% CI 1.64-2.77, 4.18, 95% CI 2.69-6.51, and 1.66, 95% CI 1.19-2.30 respectively). Adjustment for nonfatal cardiovascular events, such as myocardial infarction, stroke or heart failure, lowered these risks but incident AF remained significantly associated with all types of mortality (HR 1.7, 2.57, and 1.42 respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An association between AF and mortality was also suggested in a secondary analysis of the randomized controlled AFFIRM trial of rhythm versus rate control in AF when on-treatment analysis was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/32\">",
"     32",
"    </a>",
"    ]. Although outcomes were similar with both approaches, the presence of sinus rhythm was associated with a significant reduction in mortality (hazard ratio 0.53). A similar benefit from being in sinus rhythm (relative risk 0.44) was noted in the DIAMOND trial that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    to placebo in patients with reduced left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The coexistence of cardiovascular disease and chronic AF worsens the patient's prognosis, doubling the cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with a recent MI, the development of AF increases mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. This effect is primarily due to associated risk factors, such as HF and cardiogenic shock, not AF itself [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effect of AF in the setting of HF is less clear, since published studies have yielded conflicting results and any effect of AF to increase mortality may have diminished with better treatment of HF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link&amp;anchor=H3#H3\">",
"       \"Atrial fibrillation in patients with heart failure\", section on 'Incidence and prevalence'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, in an observational study of over 20,000 individuals in two cohorts, incident AF was associated with an increased risk of sudden cardiac death (hazard ratio 2.47, 95% CI 1.95-3.13) as well as non-sudden cardiac death (hazard ratio 2.98, 95% CI 2.52-3.53) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/361/abstract/37\">",
"     37",
"    </a>",
"    ]. This study reconfirms that AF is associated with increased all-cause mortality (with death often attributable to events related to coronary artery disease and stroke) and it advances our knowledge in that it demonstrates that there is a proportional increase in sudden death as well.",
"   </p>",
"   <p>",
"    None of these nonrandomized observations proves that AF directly causes an increase in mortality, since they cannot distinguish this possibility from AF being a marker of a confounding factor or factors that affect survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=see_link\">",
"       \"Patient information: Atrial fibrillation (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"       \"Patient information: Heart failure and atrial fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356407304\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are essential points addressed in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial fibrillation (AF) is the most common cardiac arrhythmia that can have adverse consequences related to a reduction in cardiac output (symptoms) and to atrial and atrial appendage thrombus formation (stroke and peripheral embolization). In addition, affected patients may be at increased risk for mortality. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Long-term outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypertensive heart disease and coronary heart disease are the most common underlying disorders in developed countries associated with atrial fibrillation. (See",
"      <a class=\"local\" href=\"#H440859983\">",
"       'Risk factors and disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients are classified as having new onset, paroxysmal, persistent, longstanding persistent, or permanent AF. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Essential information from the patient&rsquo;s history, physical examination, electrocardiogram, and a transthoracic echocardiogram should be obtained at the time of diagnosis and periodically during the course of the disease. Additional laboratory testing, such as thyroid stimulating hormone assay, may be necessary. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two principal management decisions for patients are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Does the patient need long-term antithrombotic therapy? All patients whose risk of embolization exceeds the risk of bleeding are candidates for such therapy. (See",
"      <a class=\"local\" href=\"#H23782659\">",
"       'Prevention of systemic embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Should the patient be managed with either a rate or a rhythm control strategy? This should be determined based on severity of symptoms, presence of structural heart disease, adequacy of rate control during episodes of atrial fibrillation, and the patient&rsquo;s preference for using antiarrhythmic drug therapy or undergoing ablation-based interventions. (See",
"      <a class=\"local\" href=\"#H356406633\">",
"       'Rate versus rhythm control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of a reversible precipitant, AF is typically recurrent.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/1\">",
"      Pritchett EL. Management of atrial fibrillation. N Engl J Med 1992; 326:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/2\">",
"      Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. J Am Coll Cardiol 1993; 22:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/3\">",
"      Lip GY, Metcalfe MJ, Rae AP. Management of paroxysmal atrial fibrillation. Q J Med 1993; 86:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/4\">",
"      Disch DL, Greenberg ML, Holzberger PT, et al. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994; 120:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/5\">",
"      Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/6\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/7\">",
"      European Heart Rhythm Association (EHRA), European Cardiac Arrhythmia Scoiety (ECAS), American College of Cardiology (ACC), et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/8\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/9\">",
"      Wilber DJ. Pursuing sinus rhythm in patients with persistent atrial fibrillation: when is it too late? J Am Coll Cardiol 2009; 54:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/10\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/11\">",
"      Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/12\">",
"      Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 1985; 254:3449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/13\">",
"      Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/14\">",
"      L&eacute;vy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99:3028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/15\">",
"      Takahashi N, Seki A, Imataka K, Fujii J. Clinical features of paroxysmal atrial fibrillation. An observation of 94 patients. Jpn Heart J 1981; 22:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/16\">",
"      Clementy J, Dulhoste MN, Laiter C, et al. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol 1992; 70:44A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/17\">",
"      EVANS W, SWANN P. Lone auricular fibrillation. Br Heart J 1954; 16:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/18\">",
"      LAMB LE, POLLARD LW. ATRIAL FIBRILLATION IN FLYING PERSONNEL. Circulation 1964; 29:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/19\">",
"      Peter RH, Gracey JG, Beach TB. A clinical profile of idiopathic atrial fibrillation. A functional disorder of atrial rhythm. Ann Intern Med 1968; 68:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/20\">",
"      Rostagno C, Bacci F, Martelli M, et al. Clinical course of lone atrial fibrillation since first symptomatic arrhythmic episode. Am J Cardiol 1995; 76:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/21\">",
"      Kozlowski D, Budrejko S, Lip GY, et al. Lone atrial fibrillation: what do we know? Heart 2010; 96:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/22\">",
"      Patton KK, Zacks ES, Chang JY, et al. Clinical subtypes of lone atrial fibrillation. Pacing Clin Electrophysiol 2005; 28:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/23\">",
"      Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. Hum Genet 2005; 118:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/24\">",
"      Oyen N, Ranthe MF, Carstensen L, et al. Familial aggregation of lone atrial fibrillation in young persons. J Am Coll Cardiol 2012; 60:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/25\">",
"      Israel CW, Gr&ouml;nefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/26\">",
"      Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/27\">",
"      Krahn AD, Klein GJ, Kerr CR, et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. Arch Intern Med 1996; 156:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/28\">",
"      Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/29\">",
"      Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/30\">",
"      Vidaillet H, Granada JF, Chyou Po, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/31\">",
"      Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 2011; 305:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/32\">",
"      Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/33\">",
"      Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/34\">",
"      Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/35\">",
"      Eldar M, Canetti M, Rotstein Z, et al. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 1998; 97:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/36\">",
"      Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990; 119:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/361/abstract/37\">",
"      Chen LY, Sotoodehnia N, B����kov&aacute; P, et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med 2013; 173:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1022 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_361=[""].join("\n");
var outline_f0_22_361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H356407304\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440859983\">",
"      RISK FACTORS AND DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440860004\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H541379272\">",
"      General classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H439358969\">",
"      Lone AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23782624\">",
"      Recurrent AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H122239619\">",
"      Subclinical AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Additional testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440860093\">",
"      New onset AF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23782659\">",
"      - Prevention of systemic embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356406633\">",
"      - Rate versus rhythm control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356406975\">",
"      - Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440860149\">",
"      Paroxysmal, persistent, longstanding persistent, or permanent AF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H440860157\">",
"      - Routine care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H440860182\">",
"      - Urgent care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H356407304\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1022\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1022|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/19/34098\" title=\"figure 1\">",
"      Prevalence of atrial fibrillation by sex and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/13/11486\" title=\"figure 2\">",
"      Mortality men women AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1022|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/45/40668\" title=\"table 1\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/23/31101\" title=\"table 2\">",
"      CHA2DS2-VASc score and stroke risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=related_link\">",
"      Mechanisms of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=related_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_22_362="Necrotizing soft tissue infections";
var content_f0_22_362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Necrotizing soft tissue infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/22/362/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/362/contributors\">",
"     Dennis L Stevens, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/362/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/22/362/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/362/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/22/362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/22/362/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/22/362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing soft tissue infections include necrotizing forms of cellulitis, myositis, and fasciitis. These infections are characterized clinically by fulminant tissue destruction, systemic signs of toxicity, and high mortality. Accurate diagnosis and appropriate treatment must include early surgical intervention and antibiotic therapy.",
"   </p>",
"   <p>",
"    Several different names have been used to describe the various forms of necrotizing infections; this is related in part to naming based on clinical features rather than surgical or pathologic findings. It is important to consider the many different types of necrotizing infections described in the literature because these descriptions may provide clinical clues needed to for prompt intervention and management. The lay press has referred to organisms that cause necrotizing soft tissue infections as &ldquo;flesh-eating bacteria.&rdquo;",
"   </p>",
"   <p>",
"    Issues related to necrotizing cellulitis, fasciitis, and myositis will be reviewed here. Pyomyositis and myonecrosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=see_link\">",
"     \"Pyomyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing soft tissue infections are comprised of two distinct bacteriologic entities: type I (polymicrobial infection) and type II (group A streptococcal infection). There are also case reports of monomicrobial necrotizing soft tissue infections due to other organisms, including Haemophilus influenzae [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In type I infection, at least one anaerobic species (most commonly Bacteroides, Clostridium, or Peptostreptococcus) is isolated in combination with one or more facultative anaerobic streptococci (other than group A) and members of the Enterobacteriaceae (eg, E. coli, Enterobacter, Klebsiella, Proteus) (",
"      <a class=\"graphic graphic_table graphicRef83456 \" href=\"UTD.htm?39/6/40044\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. An obligate aerobe, such as P. aeruginosa, is only rarely a component of such a mixed infection. Necrotizing fasciitis of the head and neck is usually caused by mouth anaerobes, such as Fusobacteria, anaerobic streptococci, Bacteroides, and spirochetes. Fournier&rsquo;s gangrene is caused by facultative organisms (E. coli, Klebsiella, enterococci), along with anaerobes (Bacteroides, Fusobacterium, Clostridium, anaerobic or microaerophilic streptococci) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/7\">",
"       7",
"      </a>",
"      ]. Aeromonas hydrophila has been associated with traumatic lesions in fresh water, and Vibrio vulnificus can cause necrotizing fasciitis in association with seawater injuries (Gulf coast and South Atlantic seaboard) of among patients with cirrhosis who ingest raw oysters [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In type II infection (also known as hemolytic streptococcal gangrene), group A streptococci or other beta-hemolytic streptococci are isolated alone or in combination with other species, most commonly S. aureus. In communities with relatively high prevalence of CA-MRSA infection, this organism is also a potential cause of necrotizing infection [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/9\">",
"       9",
"      </a>",
"      ]. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus (MRSA) as a monomicrobial infection has also been described [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important virulence determinant of GAS, M protein, is a filamentous protein anchored to the cell membrane. M protein has antiphagocytic properties. Many M types of GAS have been associated with necrotizing fasciitis; types 1 and 3 are most common [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. These strains can produce one or more of the pyrogenic exotoxins A, B, or C [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Necrotizing fasciitis caused by these strains is associated with streptococcal toxic shock syndrome in about 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/10,11,14\">",
"     10,11,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Group A streptococci may localize to the exact site of muscle injury due to increased surface expression of vimentin, which specifically binds the microbe. In an in vitro model, investigators demonstrated that injured skeletal muscle cells in tissue culture, increased adherence of GAS twofold due to specific binding of GAS by vimentin on the surface of these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pyrogenic exotoxins lead to cytokine production, which may explain some of the clinical findings of necrotizing fasciitis. The exotoxins bind to the MHC class II portion of antigen presenting cells, such as macrophages. This complex can then bind to a specific V beta segment of the T cell receptor in the absence of classical antigen processing by the macrophage [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, pyrogenic exotoxins are superantigens and cause rapid proliferation of T cells bearing specific V beta repertoires. Such stimulation of the host's immune cells is associated with production of both monokines (tumor necrosis factor-alpha, IL-1, and IL- 6) and lymphokines (IL-2 and tumor necrosis factor-beta) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/17\">",
"     17",
"    </a>",
"    ]. Expression of these cytokines in vivo probably contributes to shock, tissue destruction, and organ failure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41193?source=see_link\">",
"     \"Group A streptococcus: Virulence factors and pathogenic mechanisms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7689466\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of necrotizing infections is described in the following sections.",
"   </p>",
"   <p>",
"    The possibility of an association between use of nonsteroidal antiinflammatory drugs (NSAIDs) and development or progression of streptococcal necrotizing infection has been raised [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. It is unclear whether this association is attributable to inhibition of neutrophil function and augmentation of cytokine release (eg, tumor necrosis factor), or whether the association is secondary to use of NSAIDs for pain and fever following onset of infection. One review of the literature including five prospective studies demonstrated no correlation between NSAIDs and necrotizing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/22\">",
"     22",
"    </a>",
"    ]. In either case, NSAIDs may mask the usual signs of inflammation, thereby delaying the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6762906\">",
"    <span class=\"h2\">",
"     Necrotizing fasciitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are an estimated 3.5 cases of necrotizing fasciitis per 100,000 persons, with a case-fatality rate of 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/23\">",
"     23",
"    </a>",
"    ]. Conditions associated with necrotizing soft tissue infection include diabetes, drug use, obesity, immunosuppression, recent surgery, and traumatic wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/4\">",
"     4",
"    </a>",
"    ]. In the United States, there are no convincing data that suggest an increase incidence of necrotizing fasciitis; in New Zealand, the incidence increased from 0.18 to 1.68 per 100,000 per year between 1990 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/24\">",
"     24",
"    </a>",
"    ]. In New Zealand the prevalence was similar among different ethnic groups, but the mortality was greater among older adults and native Pacific Islanders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, in the United States and Scotland, mini-epidemics of necrotizing fasciitis and gas gangrene, caused by Clostridium sordellii and C. novyii, respectively, have been reported among drug abusers injecting black tar heroin subcutaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes is a particularly important risk factor; several forms of necrotizing infection have been described more frequently among diabetics. These include nonclostridial anaerobic cellulitis, synergistic necrotizing cellulitis, and type I necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These infections occur most frequently in the lower extremities. In addition, diabetic patients are also predisposed to developing necrotizing fasciitis in the head and neck region and the perineum.",
"   </p>",
"   <p>",
"    There are two bacterial forms of necrotizing fasciitis: type I and type II. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Microbiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I necrotizing fasciitis is a mixed infection caused by aerobic and anaerobic bacteria. Risk factors include diabetes, peripheral vascular disease (PVD), immune compromise, and recent surgery. Patients with diabetes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PVD frequently have lower extremity involvement.",
"     </li>",
"     <li>",
"      Type II necrotizing fasciitis due to group A streptococcus (GAS) either alone or in combination with other species, most commonly S. aureus. It can occur among healthy individuals with no past medical history, in any age group [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/6\">",
"       6",
"      </a>",
"      ]. Predisposing factors include a history of skin injury, such as laceration or burn, blunt trauma, recent surgery, childbirth, injection drug use, and varicella infection (chickenpox) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. In cases with no clear portal of entry, the pathogenesis of infection likely consists of hematogenous translocation of GAS from the throat (asymptomatic or symptomatic pharyngitis) to a site of blunt trauma or muscle strain [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the 1990s, there was a dramatic increase in the number of invasive infections caused by GAS. In one Canadian report, the incidence of GAS necrotizing fasciitis increased from 0.085 to 0.4 per 100,000 between 1991 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/14\">",
"     14",
"    </a>",
"    ]. Most cases were community-acquired; 20 percent were nosocomial or acquired in a nursing home. Almost one-half of patients had streptococcal toxic shock syndrome; this rate is similarly noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective review of 14 adults with necrotizing fasciitis due to community-associated MRSA, risk factors for infection included injection drug use (43 percent), diabetes (21 percent), hepatitis C infection (21 percent), malignancy (7 percent), and HIV infection (7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6762913\">",
"    <span class=\"h2\">",
"     Necrotizing myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing myositis (spontaneous gangrenous myositis) is relatively rare. In one report only 21 cases were documented between 1900 to 1985; in a second series of over 20,000 autopsies, only four cases were found [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The infection occurs in all age groups and affects males and females equally. It may be preceded by skin abrasions, blunt trauma, or heavy exercise. Most patients are otherwise healthy; underlying conditions such as diabetes mellitus or immune deficiency do not appear increase risk for this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/33\">",
"     33",
"    </a>",
"    ]. Associated mortality is high (80 to 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25044783\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early recognition of necrotizing infection is critical; rapid progression to extensive destruction can occur, leading to systemic toxicity, limb loss,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death (",
"    <a class=\"graphic graphic_table graphicRef68260 \" href=\"UTD.htm?30/53/31580\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83463 \" href=\"UTD.htm?43/4/44109\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/11,12,30\">",
"     11,12,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3656745\">",
"    <span class=\"h2\">",
"     Necrotizing cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forms of necrotizing cellulitis include anaerobic infection and Meleney's synergistic gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/5,20,36-41\">",
"     5,20,36-41",
"    </a>",
"    ]. Anaerobic cellulitis may be divided into two groups: clostridial anaerobic cellulitis and nonclostridial anaerobic cellulitis.",
"   </p>",
"   <p>",
"    Clostridial anaerobic cellulitis is usually caused by C. perfringens; less frequently, it is caused by C. septicum. Organisms are introduced into subcutaneous tissue via trauma, surgical contamination, or spread of infection from the bowel to the perineum, abdominal wall, or lower extremities. The presence of foreign debris",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrotic tissue in the depths of a wound provides a suitable anaerobic milieu for clostridial proliferation. The onset is gradual, but subsequently the process may spread rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/42\">",
"     42",
"    </a>",
"    ]. Characteristic features include thin, dark, sometimes foul-smelling wound drainage (often containing fat globules) and tissue gas formation. Pain, swelling, and systemic toxicity are not prominent features, and the relative mildness helps distinguish the process from true gas gangrene. Crepitus is observed in the skin, but there is sparing of the fascia and deep muscles. Surgical exploration and debridement are required to distinguish between anaerobic cellulitis and fasciitis or myonecrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonclostridial anaerobic cellulitis is caused by various non-spore forming anaerobic bacteria (eg, Bacteroides species, peptostreptococci, and others) either alone or as mixed infections with facultative organisms (coliform bacilli, various streptococci, staphylococci). The clinical features are similar to those of clostridial anaerobic cellulitis.",
"   </p>",
"   <p>",
"    Meleney's synergistic gangrene is a rare infection that occurs in postoperative patients. It is characterized by a slowly expanding indolent ulceration that is confined to the superficial fascia. It results from a synergistic interaction between Staphylococcus aureus and microaerophilic streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Necrotizing fasciitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4730749\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing fasciitis is an infection of the deeper tissues that results in progressive destruction of the muscle fascia and overlying subcutaneous fat; muscle tissue is frequently spared because of its generous blood supply [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/37\">",
"     37",
"    </a>",
"    ]. Infection typically spreads along the muscle fascia due to its relatively poor blood supply; initially the overlying tissue can appear unaffected. It is this feature that makes necrotizing fasciitis difficult to diagnose without surgical intervention.",
"   </p>",
"   <p>",
"    Necrotizing fasciitis is usually an acute process but rarely may follow a subacute progressive course. The affected area may be erythematous (without sharp margins), swollen, warm, shiny, and exquisitely tender [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/43\">",
"     43",
"    </a>",
"    ]. Pain out of proportion to physical exam findings may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/12,30\">",
"     12,30",
"    </a>",
"    ]. Lymphangitis and lymphadenitis are infrequent.",
"   </p>",
"   <p>",
"    The process progresses rapidly over several days, with changes in skin color from red-purple to patches of blue-gray. Within three to five days after onset, skin breakdown with bullae (containing thick pink or purple fluid) and frank cutaneous gangrene can be seen. By this time the involved area is no longer tender but has become anesthetic secondary to thrombosis of small blood vessels and destruction of superficial nerves in the subcutaneous tissue. The development of anesthesia may precede the appearance of skin necrosis and provide a clue to the presence of necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Marked swelling and edema may produce a compartment syndrome with complicating myonecrosis requiring fasciotomy. Measurement of compartment pressure may aid the evaluation early in the course of infection when marked pain and swelling are present without concomitant skin changes that would indicate the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/36\">",
"     36",
"    </a>",
"    ]. Subcutaneous gas is often present in the polymicrobial form of necrotizing fasciitis, particularly in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6762875\">",
"     'Necrotizing myositis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most cases of necrotizing fasciitis involve a single site of soft tissue infection; multifocal necrotizing fasciitis has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/44\">",
"     44",
"    </a>",
"    ]. Most cases were caused by gram-positive cocci; Vibrio vulnificus may also be associated with multifocal infection. It is uncertain whether some of these cases were related to complications of the single site infection.",
"   </p>",
"   <p>",
"    In advanced infection, fever, tachycardia, and systemic toxicity are generally observed, with temperature elevation in the range of 38.9&deg; to 40.5&deg;C (102&deg; to 105&deg;F). Other symptoms include malaise, myalgias, diarrhea, and anorexia. Hypotension may be present initially or develop with progressive infection.",
"   </p>",
"   <p>",
"    There are two bacterial forms of necrotizing fasciitis: type I and type II. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Microbiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I necrotizing fasciitis is a mixed infection caused by aerobic and anaerobic bacteria. Risk factors include diabetes, peripheral vascular disease (PVD), immune compromise, and recent surgery. Patients with diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PVD frequently have lower extremity involvement. Necrotizing fasciitis in the setting of surgical wound infection is characterized by a copious drainage, dusky and friable subcutaneous tissue, and pale, devitalized fascia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type I necrotizing fasciitis can also occur in the head and neck region or in the perineum:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical necrotizing fasciitis of the neck can result from a breach in oropharynx mucous membrane integrity following surgery or instrumentation, or in the setting of odontogenic infection. In one study including 45 patients with cervical necrotizing fasciitis, most were attributable to mixed aerobic and anaerobic bacteria. The majority of cases were of dental origin (78 percent); the remaining cases were of pharyngeal origin or occurred after surgery or trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/38\">",
"       38",
"      </a>",
"      ]. Fasciitis spread to the face (22 percent), lower neck (56 percent), and mediastinum (40 percent). In a separate study, 28 percent of patients with necrotizing fasciitis of the head and neck developed mediastinitis; factors which contributed to mediastinal involvement included prior corticosteroid use, infection by gas producing microbes, and a pharyngeal focus of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/45\">",
"       45",
"      </a>",
"      ]. Cervical (head and neck) necrotizing fasciitis is usually a mixed (Type I) infection. However, group A streptococcus (S. pyogenes) can also cause monomicrobial necrotizing fasciitis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Type II'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Bacterial penetration into the fascial compartments of the head and neck region can also result in Ludwig's angina, a rapidly expanding inflammation in the submandibular and sublingual spaces. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"       \"Deep neck space infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Necrotizing infection of the male perineum, known as Fournier's gangrene, can result from a breach in the integrity of the gastrointestinal or urethral mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. Infection can occur in all age groups but is most common in older men. Necrotizing infection involving the labia and perineum can also occur in females, particularly in the setting of diabetes. Fournier's gangrene begins abruptly with severe pain and may spread rapidly to the anterior abdominal wall, the gluteal muscles and, in males, onto the scrotum and penis (",
"      <a class=\"graphic graphic_picture graphicRef58093 \" href=\"UTD.htm?37/46/38624\">",
"       picture 1",
"      </a>",
"      ). In the setting of Fournier's gangrene, early aggressive drainage or debridement is essential [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/39,40,46\">",
"       39,40,46",
"      </a>",
"      ]. Affected patients may require cystostomy, colostomy, or orchiectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Synergistic necrotizing cellulitis is a variant of necrotizing fasciitis type I that involves the skin, muscle, fat, and fascia. It is usually occurs on the legs or perineum; diabetes is a known risk factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II necrotizing fasciitis is caused by group A streptococcus or other beta-hemolytic streptococci either alone or in combination with other pathogens, most commonly S. aureus; it has also been referred to as \"streptococcal gangrene\" [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/20\">",
"     20",
"    </a>",
"    ]. The clinical manifestations are as described above. (See",
"    <a class=\"local\" href=\"#H4730749\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6762875\">",
"    <span class=\"h2\">",
"     Necrotizing myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing myositis (also called spontaneous gangrenous myositis) is an aggressive, necrotizing infection of skeletal muscle caused by group A streptococcus or other beta-hemolytic streptococci. It may be preceded by skin abrasions, blunt trauma, or heavy exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The clinical presentation consists of fever, exquisite pain, and swelling of the affected muscle with induration. Initially the overlying skin may be uninvolved, but later in the course erythema, warmth, petechiae, bullae, and vesicles develop.",
"   </p>",
"   <p>",
"    The infection can progress over several hours to involve contiguous muscle groups and soft tissue. Onset of hypotension may occur rapidly with development of streptococcal toxic shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/47\">",
"     47",
"    </a>",
"    ]. In many patients, hypotension and renal failure precede the cutaneous manifestations by four to eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with spontaneous gangrenous myositis do not have evidence of gas formation in tissue on physical or radiographic examination; this is in contrast to clostridial myonecrosis, in which gas formation is observed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2407670\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings are generally nonspecific. Abnormalities may include leukocytosis with a marked left shift, coagulopathy, and elevations in the serum creatine kinase (CK), lactate, and creatinine concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/12,48-50\">",
"     12,48-50",
"    </a>",
"    ]. These findings, together with the clinical findings described above, should prompt surgical exploration. Once the decision is made that surgical exploration is warranted, it is critical to proceed rather than delay to obtain radiographic imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of necrotizing soft tissue infection cannot be predicted reliably using laboratory parameters, particularly in the setting of early infection. One small retrospective study describing a series of laboratory risk indicators reported a high specificity and negative predictive value for this scoring tool [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/51\">",
"     51",
"    </a>",
"    ], although subsequent data have demonstrated limited sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17594221\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing infection should be considered in patients with clinical manifestations as described above. It is important to consider necrotizing involvement of the muscle or fascia in the setting of fever, toxicity, soft tissue involvement with severe pain (out of proportion to skin findings in some cases), crepitus, rapid progression of clinical manifestations, and elevated serum creatine kinase (CK) level. Laboratory studies and blood cultures should be sent as outlined in the following sections. However, the diagnosis of necrotizing fasciitis is established surgically, with visualization of fascial planes and muscle tissue in the operating room. While obtaining a frozen section tissue biopsy at the bedside may be a useful adjunct in establishing a diagnosis of necrotizing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/54\">",
"     54",
"    </a>",
"    ], data for the efficacy this practice are limited and false-negative results may be obtained if deep tissue is not sampled adequately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2407621\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical exploration is the",
"    <strong>",
"     only",
"    </strong>",
"    way to definitively establish the diagnosis of necrotizing infection and distinguish it from other entities (",
"    <a class=\"graphic graphic_table graphicRef83463 \" href=\"UTD.htm?43/4/44109\">",
"     table 3",
"    </a>",
"    ). In addition, prompt surgical exploration facilitates early debridement and allows material to be obtained for appropriate cultures. Radiographic imaging studies can be useful to help determine whether muscle tissue is involved in some cases, but are not adequate for definitive evaluation of the fascia and should not delay surgical intervention when there is crepitus on examination or clinical evidence of progressive soft tissue infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17594113\">",
"    <span class=\"h2\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures are routinely positive in patients with necrotizing myositis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/33\">",
"     33",
"    </a>",
"    ], and they are also positive in approximately 60 percent of patients with type II necrotizing fasciitis (eg, due to group A streptococcus or other beta-hemolytic streptococci). Among patients with type I necrotizing fasciitis (eg, polymicrobial infection), the yield is lower (20 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of polymicrobial infection, blood culture findings may not reflect all organisms involved. Aspiration of skin or bullae for Gram stain and culture may also be useful, although this approach is not as reliable for microbiologic diagnosis as deep cultures obtained at surgery.",
"   </p>",
"   <p>",
"    Surgical exploration should",
"    <strong>",
"     not",
"    </strong>",
"    be delayed while awaiting results of blood cultures or skin aspirates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2407751\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic pathologic features of necrotizing fasciitis include extensive tissue destruction, thrombosis of blood vessels, abundant bacteria spreading along fascial planes, and infiltration of acute inflammatory cells. The relative concentrations of bacteria and neutrophils seen on histopathologic examination of resected tissue may have prognostic importance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristic histopathologic findings of necrotizing myositis include degeneration and necrosis of skeletal muscle fibers, infiltration of granulocytes, and numerous bacteria in areas of muscle necrosis (",
"    <a class=\"graphic graphic_picture graphicRef53989 \" href=\"UTD.htm?30/61/31702\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic imaging studies can be useful to help determine whether muscle tissue is involved, but should not delay surgical intervention when there is crepitus on examination or clinical evidence of progressive soft tissue infection.",
"   </p>",
"   <p>",
"    Radiographic imaging studies, such as soft tissue x-rays, computed tomography (CT) scanning, and magnetic resonance imaging (MRI), are most helpful if gas is visualized in the tissue; this seen most frequently in type I necrotizing fasciitis or gas gangrene caused by clostridia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The most expedient radiographic approach to assess for the presence of gas in the fascial planes is non-contrast CT examination; MRI is not as useful as CT to detect this finding. In addition, MRI can be overly sensitive; it tends to overestimate deep tissue involvement and therefore cannot be used to reliably distinguish between necrotizing cellulitis and deeper infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/58\">",
"     58",
"    </a>",
"    ]. Ultrasound is useful to detect localized abscesses, but has not been well studied in necrotizing fasciitis.",
"   </p>",
"   <p>",
"    The presence of gas in the fascial planes is a highly specific finding, but not very sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/4\">",
"     4",
"    </a>",
"    ]. More often, imaging studies demonstrate soft tissue swelling, which may also be seen in the setting of trauma or following surgery. In such cases, the diagnosis of necrotizing fasciitis or myonecrosis can be established only by surgical exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7689343\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Items included in the differential diagnosis are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef68260 \" href=\"UTD.htm?30/53/31580\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83463 \" href=\"UTD.htm?43/4/44109\">",
"     table 3",
"    </a>",
"    ). In addition to soft tissue infection, other possible diagnoses include deep venous thrombosis, septic arthritis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    induced skin necrosis, brown recluse spider bite, and gangrene with secondary infection.",
"   </p>",
"   <p>",
"    Distinguishing necrotizing myositis (spontaneous gangrenous myositis) from necrotizing fasciitis may be difficult as skeletal muscle and fascia are involved in both syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/12,30,35\">",
"     12,30,35",
"    </a>",
"    ]. Necrotizing myositis primarily involves skeletal muscle, whereas necrotizing fasciitis primarily involves fascia. The development of anesthesia may precede the appearance of skin necrosis and provide a clue to the presence of necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Necrotizing myositis may also be confused with pyomyositis. These differ in that pyomyositis is characterized by abscess formation in skeletal muscle rather than gangrenous necrosis. In addition, pyomyositis is usually caused by Staphylococcus aureus and is generally associated with less systemic toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=see_link\">",
"     \"Pyomyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of necrotizing infection consists of early and aggressive surgical exploration and debridement of necrotic tissue, together with broad spectrum empiric antibiotic therapy and hemodynamic support. Surgery is indicated in the setting of severe pain, toxicity, fever, and elevated serum creatine kinase (CK) level, with or without radiographic evidence of fasciitis. Use of antibiotic therapy without debridement is associated with a mortality rate approaching 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/4\">",
"     4",
"    </a>",
"    ]. Hemodynamic instability may require aggressive supportive care with fluids and vasopressors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing infections of the skin and fascia are surgical emergencies. Radiographic imaging studies should not delay surgical intervention when there is crepitus on examination or clinical evidence of progressive soft tissue infection.",
"   </p>",
"   <p>",
"    The goal of operative management is to perform aggressive debridement of all necrotic tissue until healthy, viable (bleeding) tissue is reached. Tissue obtained in the operating room should be sent for Gram stain and culture. Subsequently, the wound is covered with a sterile dressing, re-evaluated in the operating room approximately 24 hours later, and aggressively debrided again if necrotic tissue is present [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/43\">",
"     43",
"    </a>",
"    ]. The wound is closed after all necrotic tissue is completely debrided. In some cases, allografting or myocutaneous tissue reconstruction is required to cover the defect. For severe necrotizing infections involving the digits or extremities, amputation may be required to control the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/4\">",
"     4",
"    </a>",
"    ]. Issues related to reconstructive procedures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12521?source=see_link\">",
"     \"Principles of grafts and flaps for reconstructive surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to empiric antibiotic therapy for necrotizing infection is uncertain; data are limited since most clinical trials exclude such patients. In general, empiric treatment of necrotizing infection should consist of broad-spectrum antimicrobial therapy, including activity against gram-positive, gram-negative, and anaerobic organisms; special consideration for group A streptococcus and Clostridium species should be taken [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/4\">",
"     4",
"    </a>",
"    ]. Acceptable regimens include administration of a carbapenem or",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor (",
"    <a class=\"graphic graphic_table graphicRef67894 \" href=\"UTD.htm?7/21/7517\">",
"     table 4",
"    </a>",
"    ), together with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (dosed at 600 to 900 mg intravenously every eight hours, for its antitoxin effects against toxin-elaborating strains of streptococci and staphylococci) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/30,59-64\">",
"     30,59-64",
"    </a>",
"    ], as well as an agent with activity against methicillin-resistant S. aureus (MRSA) (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef57196 \" href=\"UTD.htm?39/12/40139\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Options for carbapenems include imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    ; options for",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitors include",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"      piperacillin",
"     </a>",
"     /tazobactam,",
"    </span>",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"      ampicillin",
"     </a>",
"     /sulbactam,",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     ticarcillin/clavulanate.",
"    </span>",
"    Patients with hypersensitivity to these agents may be treated either with an aminoglycoside or a fluoroquinolone, plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Antibiotic treatment should be tailored to Gram stain, culture, and sensitivity results when available. In the setting of known group A streptococcal or other beta-hemolytic streptococcal infection, treatment may be narrowed to the combination of penicillin (4 million units intravenously every four hours in adults &gt;60 kg in weight and with normal renal function) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 to 900 mg intravenously every eight hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/30\">",
"     30",
"    </a>",
"    ]. Therapy against MRSA may be discontinued after methicillin-resistant staphylococcal infection has been excluded.",
"   </p>",
"   <p>",
"    The optimal duration of antibiotic treatment has not been defined in clinical trials. Antibiotics should be continued until no further debridements are needed and the patient&rsquo;s hemodynamic status has normalized; this duration must be tailored to individual patient circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) contains neutralizing antibodies against some streptococcal superantigens and clostridial toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Use of high-dose IVIG (up to",
"    <span class=\"nowrap\">",
"     2g/kg)",
"    </span>",
"    appears to be beneficial in severe GAS infections, although efficacy data are not definitive [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/41,67-70\">",
"     41,67-70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8519?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of streptococcal toxic shock syndrome\", section on 'Intravenous immune globulin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a controlled trial among 21 adults with streptococcal toxic shock syndrome with or without necrotizing fasciitis, patients who received placebo had 3.6-fold higher mortality than patients who received IVIG; statistical significance was not reached (presumably because of the small sample size) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/69\">",
"     69",
"    </a>",
"    ]. IVIG dosing was 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (day one) and 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (days two and three). In an observational study comparing 30-day survival among 53 patients with streptococcal toxic shock syndrome, 30-day survival was higher among those who received IVIG than those who did not (67 versus 34 percent; p = 0.02) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/67\">",
"     67",
"    </a>",
"    ]. A greater number of patients in the IVIG group received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and were more likely to have had surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of hyperbaric oxygen treatment in the management of necrotizing fasciitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link&amp;anchor=H15#H15\">",
"     \"Hyperbaric oxygen therapy\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Postexposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group A streptococcus is a highly contagious organism; it has caused epidemics of pharyngitis and scarlet fever in schools, rheumatic fever in military recruits, and surgical wound infections in hospitalized patients. Close contacts of a case of type II necrotizing fasciitis have a high likelihood of becoming colonized with a virulent strain. The risk of developing a secondary case of fulminant necrotizing fasciitis or toxic shock syndrome is very low, but higher than for the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of postexposure prophylaxis has not been studied, and the optimal approach is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/72\">",
"     72",
"    </a>",
"    ]. For highly-susceptible individuals (such as immunocompromised individuals or patients with recent surgery) who are close household contacts of a patient with type II necrotizing fasciitis, administration of prophylaxis with penicillin (250 mg orally four times daily for 24 to 48 hours) is reasonable. The goal is reduction in likelihood of a secondary infection, rather than treatment of established infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25044979\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing infection is associated with considerable mortality, even with optimal therapy. The mortality rates in different studies have included 21 percent in type I necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/6\">",
"     6",
"    </a>",
"    ], 14 to 34 percent in type II necrotizing fasciitis (in which streptococcal toxic shock syndrome is commonly associated with mortality) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/10,12,14\">",
"     10,12,14",
"    </a>",
"    ], 22 percent in patients with cervical necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/38\">",
"     38",
"    </a>",
"    ], and 22 to 40 percent in patients with Fournier's gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/39,40,73\">",
"     39,40,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one retrospective study of 166 patients with necrotizing soft tissue infections, the overall mortality rate was 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/74\">",
"     74",
"    </a>",
"    ]. Predictors of mortality after multivariate analysis included white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;30,000/microL,",
"    </span>",
"    serum creatinine &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    clostridial infection, and the presence of heart disease on admission. In a second retrospective study from Taiwan, predictors of mortality were cirrhosis of the liver, soft tissue air, Aeromonas infection, age &gt;60 years, band neutrophils &gt;10 percent, activated partial thromboplastin time &gt;60 seconds, bacteremia, and creatinine &gt;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/75\">",
"     75",
"    </a>",
"    ]. The length of time from admission to surgery did not impact mortality, probably because surgical treatment in all patients was instituted within 24 hours of admission. In earlier studies, a delay in surgery for more than 24 hours was a risk factor for mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/6\">",
"     6",
"    </a>",
"    ]. In general, infection involving the head, neck, thorax, and abdomen are associated with greater mortality due to difficulty in surgical debridement.",
"   </p>",
"   <p>",
"    Among patients with necrotizing fasciitis, the mortality rate is higher in patients with streptococcal toxic shock syndrome. This was illustrated in a series of 62 patients with GAS necrotizing fasciitis; 52 percent also had streptococcal toxic shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/22/362/abstract/10\">",
"     10",
"    </a>",
"    ]. The patients with toxic shock syndrome had a significantly higher mortality rate (28 versus 8 percent).",
"   </p>",
"   <p>",
"    Further study is needed to understand the impact of other factors that likely contribute to mortality, including the duration of time from onset of infection to definitive treatment; the type, extent and adequacy of surgical debridement; and infection of the head and neck, thorax, and abdomen (which are more complex in terms of surgical debridement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/13/210?source=see_link\">",
"       \"Patient information: Gangrene (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3655791\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Necrotizing soft tissue infections are characterized clinically by fulminant tissue destruction, systemic signs of toxicity, and high mortality rate. Conditions associated with necrotizing infection include diabetes, drug use, obesity, immunosuppression, recent surgery, and traumatic wounds. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7689466\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two bacteriologic categories of necrotizing soft tissue infections: type I (polymicrobial infection) and type II (group A or other beta-hemolytic streptococcal infection). In type I infection, at least one anaerobic species is isolated in combination with one or more facultative anaerobic streptococci (other than group A) and members of the Enterobacteriaceae (",
"      <a class=\"graphic graphic_table graphicRef83456 \" href=\"UTD.htm?39/6/40044\">",
"       table 1",
"      </a>",
"      ). In type II infection, group A streptococci or other beta-hemolytic streptococci are isolated alone or in combination with other species, most commonly S. aureus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Necrotizing cellulitis presents with thin, dark wound drainage and gas formation in the skin (but sparing of the fascia and deep muscles). The onset is gradual, but subsequently the process may spread rapidly. Pain, swelling and systemic toxicity are not prominent features; absence of these findings helps distinguish the process from true gas gangrene. Surgical exploration and debridement are required to distinguish between anaerobic cellulitis and fasciitis or myonecrosis. (See",
"      <a class=\"local\" href=\"#H3656745\">",
"       'Necrotizing cellulitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Necrotizing fasciitis is a deep infection of the subcutaneous tissue that results in progressive destruction of fascia and fat. The affected area is usually erythematous (without sharp margins), swollen, warm, shiny, and exquisitely tender. The process progresses rapidly over several days, with changes in skin color from red-purple to patches of blue-gray. Skin breakdown with bullae (containing thick pink or purple fluid) and frank cutaneous gangrene may be observed within three to five days. The development of anesthesia may precede the appearance of skin necrosis and provide a clue that the process is necrotizing fasciitis rather than cellulitis. In advanced infection, high fever and systemic toxicity are generally observed. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Necrotizing fasciitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Necrotizing myositis (also called spontaneous gangrenous myositis) is an aggressive infection of skeletal muscle. The clinical presentation consists of fever, exquisite pain, and swelling of the affected muscle with induration. Initially the overlying skin may be uninvolved, but subsequently erythema, warmth, petechiae, bullae, and vesicles may develop. The infection can progress over several hours to involve contiguous muscle groups and soft tissue. Onset of hypotension may occur rapidly with development of streptococcal toxic shock syndrome. (See",
"      <a class=\"local\" href=\"#H6762875\">",
"       'Necrotizing myositis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical exploration is the",
"      <strong>",
"       only",
"      </strong>",
"      way to definitively establish the diagnosis of necrotizing fasciitis and distinguish it from other entities. In addition, prompt surgical exploration facilitates early debridement and allows material to be obtained for appropriate cultures. Radiographic imaging studies can be useful to help determine whether muscle tissue is involved, but should not delay surgical intervention when there is crepitus on examination or clinical evidence of progressive soft tissue infection. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Radiographic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of necrotizing infection consists of early and aggressive surgical exploration and debridement of necrotic tissue, together with broad spectrum empiric antibiotic therapy and hemodynamic support. Acceptable antibiotic regimens include administration of a carbapenem or",
"      <span class=\"nowrap\">",
"       beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor (",
"      <a class=\"graphic graphic_table graphicRef67894 \" href=\"UTD.htm?7/21/7517\">",
"       table 4",
"      </a>",
"      ), together with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (600 to 900 mg intravenously every eight hours), as well as an agent with activity against MRSA (",
"      <a class=\"graphic graphic_table graphicRef57196 \" href=\"UTD.htm?39/12/40139\">",
"       table 5",
"      </a>",
"      ). Antibiotic treatment should be tailored to Gram stain, culture, and sensitivity results when available. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous immune globulin (IVIG) contains neutralizing antibodies against some streptococcal superantigens and clostridial toxins. Data on the efficacy of this agent in the setting of necrotizing infection are limited. For cases of necrotizing fasciitis due to group A streptococcus complicated by streptococcal toxic shock syndrome, we suggest administration of IVIG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/1\">",
"      McLellan E, Suvarna K, Townsend R. Fatal necrotizing fasciitis caused by Haemophilus influenzae serotype f. J Med Microbiol 2008; 57:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/2\">",
"      Resman F, Svensj&ouml; T, &Uuml;nal C, et al. Necrotizing myositis and septic shock caused by Haemophilus influenzae type f in a previously healthy man diagnosed with an IgG3 and a mannose-binding lectin deficiency. Scand J Infect Dis 2011; 43:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/3\">",
"      Stumvoll M, Fritsche A. Necrotizing fasciitis caused by unencapsulated Haemophilus influenzae. Clin Infect Dis 1997; 25:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/4\">",
"      Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 2007; 44:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/5\">",
"      Brook I, Frazier EH. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 1995; 33:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/6\">",
"      Wong CH, Chang HC, Pasupathy S, et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003; 85-A:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/7\">",
"      Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg 2000; 87:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/8\">",
"      Hau V, Ho CO. Necrotising fasciitis caused by Vibrio vulnificus in the lower limb following exposure to seafood on the hand. Hong Kong Med J 2011; 17:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/9\">",
"      Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/10\">",
"      Darenberg J, Luca-Harari B, Jasir A, et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 2007; 45:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/11\">",
"      Chelsom J, Halstensen A, Haga T, H&oslash;iby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994; 344:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/12\">",
"      Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/13\">",
"      Hauser AR, Stevens DL, Kaplan EL, Schlievert PM. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 1991; 29:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/14\">",
"      Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997; 103:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/15\">",
"      Bryant AE, Bayer CR, Huntington JD, Stevens DL. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. J Infect Dis 2006; 193:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/16\">",
"      Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/17\">",
"      Hackett SP, Stevens DL. Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor-beta synthesis. J Infect Dis 1993; 168:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/18\">",
"      Stevens DL, Bryant AE, Hackett SP, et al. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996; 173:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/19\">",
"      Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995; 21:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/20\">",
"      Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/21\">",
"      Bouza E, Bernaldo de Quir&oacute;s JC, Rodr&iacute;guez Cr&eacute;ixems M, Quintans A. Fulminant myonecrosis due to Streptococcus pyogenes in a previously healthy patient. Eur J Clin Microbiol Infect Dis 1988; 7:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/22\">",
"      Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 2003; 82:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/23\">",
"      O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007; 45:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/24\">",
"      Das DK, Baker MG, Venugopal K. Increasing incidence of necrotizing fasciitis in New Zealand: a nationwide study over the period 1990 to 2006. J Infect 2011; 63:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/25\">",
"      Kimura AC, Higa JI, Levin RM, et al. Outbreak of necrotizing fasciitis due to Clostridium sordellii among black-tar heroin users. Clin Infect Dis 2004; 38:e87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/26\">",
"      McGuigan CC, Penrice GM, Gruer L, et al. Lethal outbreak of infection with Clostridium novyi type A and other spore-forming organisms in Scottish injecting drug users. J Med Microbiol 2002; 51:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/27\">",
"      Hasham S, Matteucci P, Stanley PR, Hart NB. Necrotising fasciitis. BMJ 2005; 330:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/28\">",
"      Eneli I, Davies HD. Epidemiology and outcome of necrotizing fasciitis in children: an active surveillance study of the Canadian Paediatric Surveillance Program. J Pediatr 2007; 151:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/29\">",
"      Aebi C, Ahmed A, Ramilo O. Bacterial complications of primary varicella in children. Clin Infect Dis 1996; 23:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/30\">",
"      Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995; 1:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/31\">",
"      Adams EM, Gudmundsson S, Yocum DE, et al. Streptococcal myositis. Arch Intern Med 1985; 145:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/32\">",
"      Svane S. Peracute spontaneous streptococcal myositis. A report on 2 fatal cases with review of literature. Acta Chir Scand 1971; 137:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/33\">",
"      Yoder EL, Mendez J, Khatib R. Spontaneous gangrenous myositis induced by Streptococcus pyogenes: case report and review of the literature. Rev Infect Dis 1987; 9:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/34\">",
"      Mac Laurin JP. Spontaneous streptococcal myositis associated with disseminated intravascular coagulopathy. J Am Osteopath Assoc 1977; 76:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/35\">",
"      Jahnson L, Berggren L, Bj&ouml;rsell-Ostling E, et al. Streptococcal myositis. Scand J Infect Dis 1992; 24:661.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartz MN, Pasternack MS. Cellulitis and subcutaneous tissue infections. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.1172.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/37\">",
"      Gozal D, Ziser A, Shupak A, et al. Necrotizing fasciitis. Arch Surg 1986; 121:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/38\">",
"      Mathieu D, Neviere R, Teillon C, et al. Cervical necrotizing fasciitis: clinical manifestations and management. Clin Infect Dis 1995; 21:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/39\">",
"      Laucks SS 2nd. Fournier's gangrene. Surg Clin North Am 1994; 74:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/40\">",
"      Stephens BJ, Lathrop JC, Rice WT, Gruenberg JC. Fournier's gangrene: historic (1764-1978) versus contemporary (1979-1988) differences in etiology and clinical importance. Am Surg 1993; 59:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/41\">",
"      Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992; 267:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/42\">",
"      MACLENNAN JD. The histotoxic clostridial infections of man. Bacteriol Rev 1962; 26:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/43\">",
"      Sudarsky LA, Laschinger JC, Coppa GF, Spencer FC. Improved results from a standardized approach in treating patients with necrotizing fasciitis. Ann Surg 1987; 206:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/44\">",
"      El-Khani U, Nehme J, Darwish A, et al. Multifocal necrotising fasciitis: an overlooked entity? J Plast Reconstr Aesthet Surg 2012; 65:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/45\">",
"      Petitpas F, Blancal JP, Mateo J, et al. Factors associated with the mediastinal spread of cervical necrotizing fasciitis. Ann Thorac Surg 2012; 93:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/46\">",
"      Hejase MJ, Simonin JE, Bihrle R, Coogan CL. Genital Fournier's gangrene: experience with 38 patients. Urology 1996; 47:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/47\">",
"      Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993; 269:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/48\">",
"      Simonart T, Simonart JM, Derdelinckx I, et al. Value of standard laboratory tests for the early recognition of group A beta-hemolytic streptococcal necrotizing fasciitis. Clin Infect Dis 2001; 32:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/49\">",
"      Yaghoubian A, de Virgilio C, Dauphine C, et al. Use of admission serum lactate and sodium levels to predict mortality in necrotizing soft-tissue infections. Arch Surg 2007; 142:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/50\">",
"      Butterworth SA, Murphy JJ. Necrotizing soft tissue infections--are they different in healthy vs immunocompromised children? J Pediatr Surg 2006; 41:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/51\">",
"      Wong CH, Khin LW, Heng KS, et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004; 32:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/52\">",
"      Wilson MP, Schneir AB. A Case of Necrotizing Fasciitis with a LRINEC Score of Zero: Clinical Suspicion Should Trump Scoring Systems. J Emerg Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/53\">",
"      Holland MJ. Application of the Laboratory Risk Indicator in Necrotising Fasciitis (LRINEC) score to patients in a tropical tertiary referral centre. Anaesth Intensive Care 2009; 37:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/54\">",
"      Majeski J, Majeski E. Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J 1997; 90:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/55\">",
"      Bakleh M, Wold LE, Mandrekar JN, et al. Correlation of histopathologic findings with clinical outcome in necrotizing fasciitis. Clin Infect Dis 2005; 40:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/56\">",
"      Zacharias N, Velmahos GC, Salama A, et al. Diagnosis of necrotizing soft tissue infections by computed tomography. Arch Surg 2010; 145:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/57\">",
"      Becker M, Zb&auml;ren P, Hermans R, et al. Necrotizing fasciitis of the head and neck: role of CT in diagnosis and management. Radiology 1997; 202:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/58\">",
"      Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am J Roentgenol 1998; 170:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/59\">",
"      Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/60\">",
"      EAGLE H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952; 13:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/61\">",
"      Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/62\">",
"      Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal infection: New concepts in antibiotic treatment. Int J Antimicrob Agents 1994; 4:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/63\">",
"      Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999; 18:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/64\">",
"      Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995; 20 Suppl 2:S154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/65\">",
"      Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156:3057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/66\">",
"      Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998; 26:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/67\">",
"      Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/68\">",
"      Norrby-Teglund A, Muller MP, Mcgeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005; 37:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/69\">",
"      Darenberg J, Ihendyane N, Sj&ouml;lin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/70\">",
"      Yong JM. Necrotising fasciitis. Lancet 1994; 343:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/71\">",
"      Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002; 35:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/72\">",
"      Sablier F, Slaouti T, Dr&egrave;ze PA, et al. Nosocomial transmission of necrotising fasciitis. Lancet 2010; 375:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/73\">",
"      Yeniyol CO, Suelozgen T, Arslan M, Ayder AR. Fournier's gangrene: experience with 25 patients and use of Fournier's gangrene severity index score. Urology 2004; 64:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/74\">",
"      Anaya DA, McMahon K, Nathens AB, et al. Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg 2005; 140:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/22/362/abstract/75\">",
"      Huang KF, Hung MH, Lin YS, et al. Independent predictors of mortality for necrotizing fasciitis: a retrospective analysis in a single institution. J Trauma 2011; 71:467.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7662 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_362=[""].join("\n");
var outline_f0_22_362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3655791\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7689466\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6762906\">",
"      Necrotizing fasciitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6762913\">",
"      Necrotizing myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25044783\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3656745\">",
"      Necrotizing cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Necrotizing fasciitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4730749\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Type I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6762875\">",
"      Necrotizing myositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2407670\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17594221\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2407621\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17594113\">",
"      Cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2407751\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7689343\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25044979\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3655791\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7662\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7662|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/46/38624\" title=\"picture 1\">",
"      Fourniers gangrene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/61/31702\" title=\"picture 2\">",
"      Gangrenous myositis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7662|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/6/40044\" title=\"table 1\">",
"      Microbiology necrotizing infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/53/31580\" title=\"table 2\">",
"      Differential diagnosis myositis and fasciitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/4/44109\" title=\"table 3\">",
"      Differential diagnosis necrotizing infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/21/7517\" title=\"table 4\">",
"      Empiric therapy gram negatives and anaerobes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/12/40139\" title=\"table 5\">",
"      Parenteral antibiotics for infections due to MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41193?source=related_link\">",
"      Group A streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/13/210?source=related_link\">",
"      Patient information: Gangrene (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12521?source=related_link\">",
"      Principles of grafts and flaps for reconstructive surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=related_link\">",
"      Pyomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8519?source=related_link\">",
"      Treatment of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_22_363="Common pitfalls causing missed Achilles tendon rupture";
var content_f0_22_363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common pitfalls causing missed Achilles tendon rupture",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Patient&nbsp;able to&nbsp;plantar flex their foot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient&nbsp;able to&nbsp;walk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tendon is not painful",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examiner cannot palpate a defect in the Achilles tendon",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_363=[""].join("\n");
var outline_f0_22_363=null;
var title_f0_22_364="Radiation terms defined";
var content_f0_22_364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Terms employed for measurement of ionizing radiation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Curie (Ci)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The amount of material whose atoms are undergoing a certain number of radioactive decays per unit time. One Curie, which was originally set as the number of atomic disintegrations per second in 1 gram of radium, is equal to the amount of radioactive material undergoing 3.7 x 10",
"        <sup>",
"         10",
"        </sup>",
"        disintegrations per second. This unit has been superseded by the",
"        <strong>",
"         Becquerel (Bq)",
"        </strong>",
"        . One Becquerel is equal to the amount of material&nbsp;that is undergoing 1 disintegration/second.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Roentgen (R)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The amount of x-ray or gamma ray radiation&nbsp;that produces a certain number of ionizations (ion pairs) in a fixed quantity of air. One Roentgen is the quantity of x- or gamma-radiation&nbsp;that produces, in 0.001293 grams of air, ions carrying one electrostatic unit of electrical charge.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Roentgen equivalent in man (rem)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One rem is the amount of ionizing radiation of any type that produces in man the same biologic effect as one Roentgen of x- or gamma-rays. It is equal to the absorbed dose, measured in rads, multiplied by the relative biologic effectiveness (rbe) of the radiation in question. As examples, the rbe of x- and gamma rays is 1; the rbe for alpha particles and neutrons is 20. This unit has been superseded by the",
"        <strong>",
"         Sievert (Sv)",
"        </strong>",
"        . One Sievert is equal to 100 rem.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Radiation absorbed dose (rad)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One rad is equal to the absorption of 100 ergs of ionizing radiation per gram of tissue. This unit has been superseded by the",
"        <strong>",
"         Grey (gy)",
"        </strong>",
"        . One Grey is equal to 100 rad.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_364=[""].join("\n");
var outline_f0_22_364=null;
var title_f0_22_365="Neonatal doses MRSA";
var content_f0_22_365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected parenteral drug doses for infants &le;28 days of age with suspected invasive Staphylococcus aureus infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"5\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Infants &le;7 days of age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Infants 8 to 28 days of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        BW &le;2000 g",
"       </td>",
"       <td class=\"subtitle2\">",
"        BW &gt;2000 g",
"       </td>",
"       <td class=\"subtitle2\">",
"        BW &le;2000 g",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        BW &gt;2000 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxacillin",
"        </strong>",
"       </td>",
"       <td>",
"        25 mg/kg every 12 hours",
"       </td>",
"       <td>",
"        25 mg/kg every 8 hours",
"       </td>",
"       <td>",
"        25 mg/kg every 8 hours",
"       </td>",
"       <td colspan=\"2\">",
"        25 mg/kg every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Nafcillin",
"        </strong>",
"       </td>",
"       <td>",
"        25 mg/kg every 12 hours",
"       </td>",
"       <td>",
"        25 mg/kg every 8 hours",
"       </td>",
"       <td>",
"        25 mg/kg every 8 hours",
"       </td>",
"       <td colspan=\"2\">",
"        25 mg/kg every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gentamicin",
"        </strong>",
"        *",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        5 mg/kg every 48 hours",
"       </td>",
"       <td>",
"        4 mg/kg every 24 hours",
"       </td>",
"       <td>",
"        4 to 5 mg/kg every 24 to 48 hours",
"       </td>",
"       <td colspan=\"2\">",
"        4 mg/kg every 12 to 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Linezolid",
"        </strong>",
"       </td>",
"       <td>",
"        10 mg/kg every 12 hours",
"       </td>",
"       <td>",
"        10 mg/kg every 8 hours",
"       </td>",
"       <td>",
"        10 mg/kg every 8 hours",
"       </td>",
"       <td colspan=\"2\">",
"        10 mg/kg every 8 hours",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Vancomycin",
"        </strong>",
"       </td>",
"       <td colspan=\"5\">",
"        Dosed according to serum creatinine concentration as indicated below",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Serum creatinine concentration",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;0.7",
"       </td>",
"       <td class=\"subtitle2\">",
"        0.7 to 0.9",
"       </td>",
"       <td class=\"subtitle2\">",
"        1.0 to 1.2",
"       </td>",
"       <td class=\"subtitle2\">",
"        1.3 to 1.6",
"       </td>",
"       <td class=\"subtitle2\">",
"        &gt;1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vancomycin",
"        </strong>",
"       </td>",
"       <td>",
"        15 mg/kg every 12 hours",
"       </td>",
"       <td>",
"        20 mg/kg every 24 hours",
"       </td>",
"       <td>",
"        15 mg/kg every 24 hours",
"       </td>",
"       <td>",
"        10 mg/kg every 24 hours",
"       </td>",
"       <td>",
"        15 mg/kg every 4 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BW: body weight.",
"     <br/>",
"     * Optimal, individualized dose should be based on determination of serum concentrations.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Doses may differ from those recommended by the package insert.",
"     <br/>",
"     &Delta; Add 0.2 to serum creatinine concentration for neonates &le;28 weeks of age.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: American Academy of Pediatrics. Tables of antimicrobial drug dosages. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29",
"     <sup>",
"      th",
"     </sup>",
"     ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.807.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_365=[""].join("\n");
var outline_f0_22_365=null;
var title_f0_22_366="Types ascitic fluid infection";
var content_f0_22_366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Natural history of ascitic fluid infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 302px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between spontaneous bacterial peritonitis and its variants as shown by the short-term, untreated natural history of the different conditions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from McHutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Gastrointestinal and Hepatic Infections, Surawicz CM, Owen RL (Eds), WB Saunders, Philadelphia, 1994, p. 455.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_366=[""].join("\n");
var outline_f0_22_366=null;
var title_f0_22_367="Determining BMI A";
var content_f0_22_367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Determining body mass index from weight and height",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\" rowspan=\"1\">",
"        Good weights",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Overweight",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        BMI, kg/m2",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Height, inches*",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"14\" rowspan=\"1\">",
"        Weight, pounds*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        58\"",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        191",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        59\"",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        198",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60\"",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        204",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        61\"",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        211",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        62\"",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        218",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        63\"",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        141",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        225",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        64\"",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        232",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65\"",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        240",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        66\"",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        161",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        247",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        67\"",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        178",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        223",
"       </td>",
"       <td>",
"        255",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        68\"",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        230",
"       </td>",
"       <td>",
"        262",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        69\"",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        182",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        196",
"       </td>",
"       <td>",
"        203",
"       </td>",
"       <td>",
"        236",
"       </td>",
"       <td>",
"        270",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70\"",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        181",
"       </td>",
"       <td>",
"        188",
"       </td>",
"       <td>",
"        195",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        209",
"       </td>",
"       <td>",
"        243",
"       </td>",
"       <td>",
"        278",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        71\"",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        165",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        193",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        215",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        286",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        72\"",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        199",
"       </td>",
"       <td>",
"        206",
"       </td>",
"       <td>",
"        213",
"       </td>",
"       <td>",
"        221",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        294",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        73\"",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        182",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        219",
"       </td>",
"       <td>",
"        227",
"       </td>",
"       <td>",
"        265",
"       </td>",
"       <td>",
"        302",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        74\"",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        218",
"       </td>",
"       <td>",
"        225",
"       </td>",
"       <td>",
"        233",
"       </td>",
"       <td>",
"        272",
"       </td>",
"       <td>",
"        311",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75\"",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        192",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        224",
"       </td>",
"       <td>",
"        232",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        279",
"       </td>",
"       <td>",
"        319",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        76\"",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        205",
"       </td>",
"       <td>",
"        213",
"       </td>",
"       <td>",
"        221",
"       </td>",
"       <td>",
"        230",
"       </td>",
"       <td>",
"        238",
"       </td>",
"       <td>",
"        246",
"       </td>",
"       <td>",
"        287",
"       </td>",
"       <td>",
"        328",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The health risk from any level of BMI is increased if the patient has gained more than 5 kg (11 pounds) since age 25, or if the waist circumference is above 100 cm (40 in) due to central fatness",
"    <div class=\"footnotes\">",
"     * Divide weight by 2.2 to convert pounds into kilograms; multiply height by 2.54 to convert inches into centimeters.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_22_367=[""].join("\n");
var outline_f0_22_367=null;
